Subject Index

A

A-924, a new antineoplastic amino acid derivative, 1577
Abdominal cancer *see* Cancer, abdominal
ABVD (adriamycin, bleomycin, vinblastine, and DTIC), or MOPP combined with radiotherapy in advanced Hodgkin's disease, 769
***cis*-Acid** *see* 4-(3-(2-Chloroethyl)-3-nitrosoureido)-*cis*-cyclohexanecarboxylic acid
Actinomycin D (NSC-3053)
effects of, on nucleolar morphology of Novikoff hepatoma cells from rats: a simple biologic assay, 1253
radioimmunoassay for, 585
in the treatment of metastatic osteogenic sarcoma, 499
Adenocarcinoma E0771 *see* Tumor systems in animals
Adriamycin (NSC-123127)
alone versus adriamycin and bleomycin in the treatment of advanced epidermoid carcinoma of the cervix, 1383
alone versus adriamycin plus melphalan in the treatment of advanced ovarian carcinoma, 355
in American patients with hepatocellular cancer, 1385
cardiac toxicity: a different hypothesis, 497
CCNU, bleomycin, and methylprednisolone with or without adriamycin in the treatment of renal cell carcinoma, 1591
combined with bleomycin and prednisone in the treatment of stage IV non-Hodgkin's lymphomas, 1117
combined with cyclophosphamide and followed by alternating combination therapy (methotrexate and 5-FU) for metastatic breast cancer, 1685
combined with cyclophosphamide in the treatment of advanced bladder cancer, 97
combined with cyclophosphamide or *cis*-dichlorodiammineplatinum(II) in patients with advanced cancer, 869
combined with cyclophosphamide (with or without radiation therapy) for carcinoma of the lung, 875
combined with cytosine arabinoside in the treatment of adult acute myelocytic leukemia, 89
combined with *cis*-dichlorodiammineplatinum(II) in the treatment of various human tumors, 477
combined with DTIC and cyclophosphamide in the treatment of advanced small cell lung cancer, 481
combined with DTIC: high incidence of cardiomyopathy in children treated with, 1736
combined with mechlorethamine and CCNU (NAC) and compared to bleomycin, adriamycin, CCNU, vincristine, and mechlorethamine (BACON) in the treatment of squamous lung cancer, 1623
combined with vincristine and procarbazine in previously treated patients with small cell lung carcinoma, 485
combined with vincristine and bleomycin in the treatment of men with metastatic germ-cell tumors, 1447
combined with vincristine, cyclophosphamide, methotrexate, and citrovorum factor rescue in the treatment of metastatic breast cancer, phase II study, 1527
combined with VM-26 in the treatment of metastatic transitional cell carcinoma, 87
compared to 5-FU in advanced prostatic cancer, 325
effects of, on nucleolar morphology of Novikoff hepatoma cells from rats: a simple biologic assay, 1253
and 5-FU in the treatment of advanced hepatoma, 1595
horizontal pigmented banding of the nails in association with, 499
a hypothesis concerning possible new derivatives of, with enhanced DNA-binding properties, 928
intra-arterial, preliminary clinical experiences with, 1565
and other chemotherapy for metastatic carcinoid tumors, 1699
phase II study, combined with *cis*-dichlorodiammineplatinum(II) and cyclophosphamide or with VP-16-213 in the treatment of small cell lung cancer, 93
pilot study of 2 adriamycin-based regimens in patients with advanced malignant lymphomas, 65
in previously treated adult acute leukemia, 905
response of medullary thyroid carcinomas and carcinoid tumors to, 106
in the treatment of alveolar soft part sarcoma, 77
used in combination immunochemotherapy of oat cell carcinoma of the lung, 343
Adverse effects in animals, modification of the renal toxicity of *cis*-dichlorodiammineplatinum(II) with furosemide in male F344 rats, 375
Adverse effects in man
adriamycin cardiac toxicity: a different hypothesis, 497
allergic reaction to cyclophosphamide in a mechlorethamine-sensitive patient, 495
autoregulation of L-asparaginase-induced diabetes mellitus, 1607
central nervous system disturbances after procarbazine combined with mechlorethamine, 1713
congestive heart failure, time relationship between last dose of daunorubicin and, 1411
high incidence of cardiomyopathy in children treated with DTIC and adriamycin, 1736
horizontal pigmented banding of the nails in association with adriamycin, 499
pigmented banding of the nail caused by bleomycin, 501
possible neurologic complication of DTIC, 105

Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma, 925
recovery from toxicity associated with high-dose methotrexate: prognostic factors, 797
selective protection of the gastrointestinal tract against methotrexate in patients with trophoblastic tumors, 895
severe hypotension, lack of, with VP-16-213 administered directly iv, 1411
unexpected pain syndrome during a phase I study of iv methyl-CCNU, 1413
vinblastine-related pain in tumors, 1735
DL-Alanosine (NSC-143647), pharmacologic disposition of, in mice, rats, dogs, and monkeys, 1471
Alkylating agents (*see also* specific compounds), selection of carriers for alkylating moieties to increase their antitumor specificity, 929
Amikacin (NSC-177001), combined with carbenicillin and cefazolin as an empiric therapy for febrile granulocytopenic cancer patients, 1433
Amino acid metal systems, antitumor activity of, 469
Amino acids, a new antineoplastic derivative of (A-924), 1577
S-2-(3-Aminopropylamino)ethylphosphorothioate, effect of, on tumor control and skin tolerance in the rat, 825
Androgen receptors, methods for measurement of, in human prostatic tissue, 265
2,2'-Anhydro-1-β-D-arabinofuranosyl-5-fluorocytosine (NSC-166641)
physiologic disposition of, in man, 723
tissue distribution and fate in rats, 617
Aniline mustard (NSC-18429), a new high-glucuronidase mouse tumor curable by, 909
Ann Arbor staging classification, validity of, in non-Hodgkin's lymphomas, 1023
Anticoagulation agents, heparin and polychemotherapy for treatment of lung cancer, 1399
Antiestrogen *see* Tamoxifen
Antifolates, in vivo kinetic considerations, 513
Antimetabolites (*see also* specific agents), Proceedings of the Workshop on Antimetabolites and the Central Nervous System, 505–757
Antimicrobial therapy, carbenicillin, cefazolin, and amikacin as an empiric therapy for febrile granulocytopenic cancer patients, 1433
Antisera, specificity of, produced against bleomycin, 1509
1-β-D-Arabinofuranosyluracil (NSC-68928), extraction and analytic procedures for, and its mono-, di-, and triphosphates, 643
1-β-D-Arabinofuranosyl-5-fluorocytosine (NSC-529180)
physiologic disposition of, in man, 723
tissue distribution and fate in rats, 617
5-Arylpyrimidine antifolates *see* Pyrimidine, 2,4-diamino-5-(3,4-dichlorophenyl)-6-methyl-
Asaley (NSC-167780), phase II trial of, in children with late-stage acute lymphocytic leukemia, 1373
L-Asparaginase (NSC-109229), autoregulation of diabetes mellitus induced by, 1607
Athymic (nude) mice
suppression of human myelosarcoma growth in, by a primate antiserum, 1679
toxicity of cancer chemotherapeutic agents in, 103
5-Azacytidine (NSC-102816)
combined with β-2'-deoxythioguanosine in adult acute leukemia, 915
combined with vinblastine and VP-16-213 in previously treated patients with acute nonlymphocytic leukemia, 1599
phase II study of, in solid tumors, 51, 55
phase II study of, twice weekly infusion in disseminated metastatic cancer, 1675
sc, in the treatment of refractory adult acute nonlymphoblastic leukemia, 1721
Azathioprine (NSC-39084), in the treatment of multiple myeloma in remission, 381
Azotomycin (NSC-56654), phase II study of, in sarcomas, 1719

B

Bacillus Calmette-Guérin (*see also* Methanol extraction residue of bacillus Calmette-Guérin), enhancement of antileukemic effect in L1210 leukemia with the combination of 5-FU and, 17
BACON (bleomycin, adriamycin, CCNU, vincristine, and mechlorethamine), compared to mechlorethamine, adriamycin, and CCNU (NAC) for extensive squamous lung carcinoma, 1623
Baker's antifol, phase II trial of, in metastatic sarcoma, 1485
BALB 3T3 cells, effects of geldanamycin and its derivatives on RNA-directed DNA polymerase, 815
BCNU (NSC-409962)
alone and in combination with vincristine, procarbazine, and prednisone in the primary treatment of disseminated Hodgkin's disease, 789
combined with cyclophosphamide, vincristine, and prednisone in non-Hodgkin's lymphoma, 1085
concentration in brain after ventriculocisternal perfusion, 625
BCOP (BCNU, cyclophosphamide, vincristine, and prednisone), in the treatment of non-Hodgkin's lymphoma, 1085
Benign prostatic hyperplasia
cells in culture, morphologic and immunologic studies in, 133
role of oncornaviruses in tissue from patients with, 131
search for oncogenic viruses in tissues from patients with, 119
tumor-specific immunity in patients with, 211
[*p*-[Bis(2-chloroethyl)amino]phenyl]acetic acid (NSC-71964), homo-aza-steroidal ester of, antileukemic effects of, in L1210 and P388 leukemias, 37
Bladder cancer *see* Cancer, bladder
Bleomycin (NSC-125066)
and adriamycin versus adriamycin alone in the treatment of advanced epidermoid carcinoma of the cervix, 1383
with CCNU and streptozotocin in a phase II study of patients with metastatic breast cancer, 1365
combined with adriamycin and prednisone in the treatment of stage IV non-Hodgkin's lymphomas, 1117

combined with adriamycin and vincristine in the treatment of men with metastatic germ-cell tumors, 1447
combined with adriamycin, CCNU, vincristine, and mechlorethamine (BACON) and compared to mechlorethamine, adriamycin, and CCNU (NAC) in the treatment of squamous lung cancer, 1623
combined with CCNU and methylprednisolone with or without adriamycin in the treatment of renal cell carcinoma, 1591
combined with CCNU and VM-26, enhancement of bone marrow toxicity, in patients with malignant brain tumors, 1695
combined with cyclophosphamide, vincristine, and methyl-CCNU in the treatment of advanced lung carcinoma, 59
combined with vinblastine, Raynaud's phenomenon as a side effect of treatment for testicular carcinoma, 925
continuous pelvic arterial infusion with, for squamous cell carcinoma of the cervix recurrent after radiation therapy, 1403
effects of variations in renal function on the clinical pharmacology of, administered as an iv bolus, 1631
pigmented banding of the nail caused by, 501
specificity of antisera produced against, 1509
in the treatment of renal cell carcinoma, 1585
used in combination immunochemotherapy of oat cell carcinoma of the lung, 343
Brain cancer *see* Cancer, brain
Breast cancer *see* Cancer, breast
Bronchogenic carcinoma *see* Cancer, lung
Busulfan (NSC-750), repeated single doses of, in the treatment of chronic myeloid leukemia, 43

C

Calcium leucovorin *see* Citrovorum factor
Calusterone (NSC-88536), in the treatment of advanced breast cancer, 371
CAMP (CCNU, melphalan, methotrexate, and prednisone), in the treatment of advanced breast cancer, 1603
Cancer (nonhematologic)
abdominal, whole-body computed tomography in the diagnosis of, 1537
bladder
advanced, adriamycin plus cyclophosphamide in the treatment of, 97
transitional cell, metastatic, VM-26 and adriamycin in the treatment of, 87
brain
enhancement of bone marrow toxicity of VM-26-CCNU combination by bleomycin in patients with, 1695
high-dose methotrexate and citrovorum factor rescue in the management of, 691
iv methyl-CCNU, VM-26, and cranial irradiation in the treatment of, 1715
theoretic limitations of intracarotid infusions of drugs in, 519
breast
advanced, antiestrogen tamoxifen in the treatment of, 899
advanced, calusterone in the treatment of, 371
advanced, CCNU, melphalan, methotrexate, and prednisone (CAMP) in the treatment of, 1603
advanced, evaluation of single-drug versus multiple-drug chemotherapy in the treatment of, 47
advanced, 5-FU-induced increase of total serum thyroxine and triiodothyronine levels in patients with, 1291
advanced, phase II study of dianhydrogalactitol and ICRF-159 in patients with, previously exposed to cytotoxic chemotherapy, 81
implications of the ^{99m}Tc-diphosphate bone scan for the treatment of, 1249
metastatic, adriamycin and cyclophosphamide followed by alternating combination therapy (methotrexate and 5-FU) for, 1685
metastatic, phase II study of piperazinedione in the treatment of, 1711
metastatic, phase II study of vincristine, adriamycin, cyclophosphamide, methotrexate, and citrovorum factor rescue in the treatment of, 1527
metastatic, phase II trial with bleomycin, CCNU, and streptozotocin in the treatment of, 1365
central nervous system
antimetabolites in, 657
in children, high-dose methotrexate with citrovorum factor rescue in the treatment of, 681
cervical
advanced epidermoid, adriamycin alone versus adriamycin and bleomycin in the treatment of, 1383
squamous cell, continuous pelvic arterial infusion with bleomycin for, recurrent after radiation therapy, 1403
colon, metastatic adenocarcinoma, iv methyl-CCNU and ftorafur with or without methanol extracted residue of bacillus Calmette-Guérin for, 1581
colorectal
advanced, phase II study of pyrazofurin in, 491
5-FU-refractory, phase II clinical trial of ftorafur in, 1579
gastrointestinal
metastatic, 5-FU and streptozotocin in the treatment of, 1375
phase I trial of ftorafur combined with mitomycin C or methyl-CCNU, 463
head and neck, epidermoid, *cis*-dichlorodiammineplatinum(II) in the treatment of, 359
hepatocellular, adriamycin therapy in American patients with, 1385
large bowel
advanced, phase II study of cytosine arabinoside in the treatment of, 1725
methyl-CCNU versus methyl-CCNU and 5-FU in the treatment of, 1453
lung
advanced, cyclophosphamide, vincristine, methyl-CCNU, and bleomycin in the treatment of, 59
advanced non-small cell, platinum-based polychemo-

therapy versus dianhydrogalactitol in the treatment of, 1339
advanced small cell, cyclophosphamide, adriamycin, and DTIC polychemotherapy in the treatment of, 481
combination chemotherapy with adriamycin and cyclophosphamide (with or without radiation therapy) for, 875
extensive squamous, comparative trial of bleomycin, adriamycin, CCNU, vincristine, and mechlorethamine (BACON) and mechlorethamine, adriamycin, and CCNU (NAC) in the treatment of, 1623
heparin and polychemotherapy in the treatment of, 1399
oat cell, combined modality treatment (procarbazine, vincristine, cyclophosphamide, and CCNU, or cyclophosphamide, vincristine, and methotrexate, plus radiation therapy) for: a randomized trial, 1
oat cell, immunochemotherapy of, 343
oat cell, radiation therapy after treatment with procarbazine, vincristine, cyclophosphamide, and CCNU, 1427
small cell, advances in, 333
small cell, combination chemotherapy with vincristine, adriamycin, and procarbazine in previously treated patients, 485
small cell, intensive chemotherapy with cyclophosphamide, methotrexate, and CCNU, 349
small cell, phase II clinical trial of weekly administration of VP-16-213 in, 489
small cell, phase II study of polychemotherapy regimens in the treatment of, 93
ovarian
advanced, adriamycin versus adriamycin plus melphalan in the treatment of, 355
advanced, 5-FU infusion and cyclophosphamide in the treatment of, 1573
advanced, hexamethylmelamine and 5-FU in the treatment of, 1691
advanced, treatment of, with high-dose cyclophosphamide after failure on melphalan, 1369
metastatic and recurrent, medroxyprogesterone acetate for the treatment of, 913
mustard-resistant, a randomized study of CCNU or methyl-CCNU in the treatment of, 1533
prostate
advanced, comparative trial of adriamycin and 5-FU in, 325
advanced, melphalan in the treatment of: a pilot study, 923
advanced, national randomized study of chemotherapeutic agents in, 317
advanced, radical retropubic prostatectomy, bilateral orchiectomy, estrogen therapy, and chemotherapy (5-FU and cyclophosphamide) in the treatment of, 313
advanced stage D, new steroidal alkylating agents in, 307
among blacks, characterization of, 167
analysis of prostatic fluid in, 205
culture of mammalian prostatic cells, 161
enzyme markers in, 193
epidemiologic study of, 181
evaluation of extended-field radiotherapy for, 297
metastatic, 5-FU versus CCNU in the treatment of, 1589
immunochemical studies of prostatic acid phosphatase, 201
interstitial radiation therapy of, using iridium 192 wires, 329
metastatic, evaluation of melphalan, ICRF-159, and hydroxyurea in, 311
new agents for, activated specifically by prostatic acid phosphatase, 259
preliminary studies of histologic prognosis in, 223
presenting as a pericardial tamponade, 1607
race and socioeconomic status as factors in incidence of, 187
scanning electron microscopic study of, 227
some new approaches to potential test systems for drugs against, 289
studies in the epidemiology of, 173
tumor-specific immunity in patients with, 211
renal
advanced, phase II study of vindesine sulfate in the therapy for, 1727
CCNU, bleomycin, and methylprednisolone with or without adriamycin in the treatment of, 1591
CCNU, vinblastine, thioTEPA, or bleomycin in the treatment of, 1585
metastatic, piperazinedione in the treatment of, 1731
testicular
metastatic germ-cell, treatment with adriamycin, vincristine, and bleomycin, 1447
Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for, 925
thoracic, whole-body computed tomography in the diagnosis of, 1537
thyroid, medullary, response of, to adriamycin, 106
trophoblastic, selective protection of the gastrointestinal tract against methotrexate in patients with, 895

Carbenicillin (NSC-111071), combined with cefazolin and amikacin as an empiric therapy for febrile granulocytopenic cancer patients, 1433

Carbon-adsorbed folic acid, for selective protection of the gastrointestinal tract against methotrexate in patients with trophoblastic tumors, 895

Carcinoid syndrome
malignant, use of DTIC in the treatment of, 101
a role for hemodialysis in, 107

Carcinoid tumor
metastatic, chemotherapy (including adriamycin) for, 1699
metastatic, mediastinal, treated with chemotherapy, 108
response of, to adriamycin, 106

Carcinoma *see* Cancer, type of

Cardiotoxicity *see* Adverse effects in man

Carminomycin (NSC-180024), phase I clinical study of, in soft tissue sarcomas, 1705

CAT scans, whole-body computed tomography in the diagnosis of abdominal and thoracic malignancy: review of 600 cases, 1537

CCNU (NSC-79037)
with bleomycin and streptozotocin in a phase II study of patients with metastatic breast cancer, 1365
combined with bleomycin and methylprednisolone with or without adriamycin in the treatment of renal cell carcinoma, 1591
combined with cyclophosphamide and methotrexate (CMC) in the treatment of small cell lung carcinoma, 349
combined with mechlorethamine and adriamycin (NAC) and compared to bleomycin, adriamycin, CCNU, vincristine, and mechlorethamine (BACON) in the treatment of squamous lung cancer, 1623
combined with melphalan, methotrexate, and prednisone (CAMP) in the treatment of advanced breast cancer, 1603
combined with VM-26 and bleomycin, enhancement of bone marrow toxicity, in patients with malignant brain tumors, 1695
and procarbazine, vincristine, and cyclophosphamide combined with radiation therapy in the treatment of extensive oat cell lung cancer, 1427
with procarbazine, vincristine, and cyclophosphamide followed by radiation therapy for oat cell carcinoma of the lung, 1
in the treatment of mustard-resistant ovarian adenocarcinoma, 1533
in the treatment of renal cell carcinoma, 1585
used in combination immunochemotherapy of oat cell carcinoma of the lung, 343
versus 5-FU in the treatment of advanced prostatic cancer, 1589
Cefazolin, combined with carbenicillin and amikacin as an empiric therapy for febrile granulocytopenic cancer patients, 1433
Central nervous system (*see also* Adverse effects in man)
physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the, 527
Proceedings of the Workshop on Antimetabolites and the Central Nervous System, 505–757
Central nervous system cancer *see* Cancer, central nervous system; Leukemia, central nervous system
Cervical cancer *see* Cancer, cervical
Chlorambucil (NSC-3088), serum displacing agents used in combination with, in cancer chemotherapy, 1407
Chlorasquin (NSC-529861), effect of, versus enzymatic folate depletion on folate and thymidine enzymes in cultured mammalian cells, 539
4-(3-(2-Chloroethyl)-3-nitrosoureido)-*cis*-cyclohexanecarboxylic acid (NSC-153174), a water-soluble nitrosourea derivative, cellular response to treatment with, 1513
***p*-Chlorophenoxyisobutyric acid (NSC-1149)**, used as a serum displacing agent in combination with chlorambucil, 1407
***p*-Chlorophenoxyacetic acid (NSC-8769)**, used as a serum displacing agent in combination with chlorambucil, 1407
Citrovorum factor (NSC-3590)
combined with DDMP [pyrimidine, 2,4-diamino-5-(3,4-dichlorophenyl)-6-methyl-], toxicity and responsiveness of Sarcoma 180 to, 1325
combined with methotrexate in the treatment of alveolar soft part sarcoma, 77
combined with methotrexate, vincristine, adriamycin, and cyclophosphamide in the treatment of metastatic breast cancer, phase II study, 1527
combined with methotrexate, vincristine, cyclophosphamide, and cytosine arabinoside in the treatment of diffuse histiocytic lymphoma, 1109
and high-dose methotrexate, incidence of drug-related deaths secondary to, 745
and high-dose methotrexate, recovery from toxicity associated with: prognostic factors, 797
with high-dose methotrexate therapy: a pharmacologic perspective in murine tumor models, 565
with methotrexate in the treatment of osteogenic sarcoma, 675
microbiologic assay for, 597
new "rescue" with massive doses of, for potentially lethal methotrexate toxicity, 749
radioimmunoassay for, 585
rescue and high-dose methotrexate in the management of brain tumors, 691
rescue, pharmacokinetics of high-dose methotrexate with, 1665
rescue, with high-dose methotrexate in the treatment of central nervous system tumors in children, 681
rescue, with high-dose methotrexate: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity, 779
rescue, with weekly methotrexate: effect of alkalinization on nephrotoxicity; pharmacokinetics in the central nervous system; and use in central nervous system non-Hodgkin's lymphoma, 695
Colon cancer *see* Cancer, colon
Colorectal cancer *see* Cancer, colorectal
Combination chemotherapy (*see also* individual drugs), on determining levels of treatment to optimize the probability of favorable response, 849
COM (cyclophosphamide, vincristine, and methotrexate), followed by radiation and compared to procarbazine, vincristine, cyclophosphamide, and CCNU followed by radiation in the treatment of oat cell carcinoma of the lung, 1
Congestive heart failure *see* Adverse effects in man
COP (cyclophosphamide, vincristine, and prednisone), in the treatment of non-Hodgkin's lymphoma, 1085
Corticosteroids, compounds altering the activity of, 1231
Corynebacterium parvum, used in combination immunochemotherapy of oat cell carcinoma of the lung, 343
Cyclocytidine (NSC-145668)
distribution and excretion of, in experimental animals, 805
phase I–II study of, 437
Cycloleucine (NSC-1026), observations on the human pharmacology of, 1561
Cyclophosphamide (NSC-26271)
allergic reaction to, in a mechlorethamine-sensitive patient, 495
alone, combined with estramustine phosphate, or combined with diethylstilbestrol in the treatment of prostatic cancer, 317

with CCNU, vincristine, and procarbazine followed by radiation for oat cell carcinoma of the lung, 1
combined with adriamycin and followed by alternating combination therapy (methotrexate and 5-FU) for metastatic breast cancer, 1685
combined with adriamycin in patients with advanced cancer, 869
combined with adriamycin in the treatment of advanced bladder cancer, 97
combined with adriamycin (with or without radiation therapy) for carcinoma of the lung, 875
combined with DTIC and adriamycin in the treatment of advanced small cell lung cancer, 481
combined with 5-FU, radical retropubic prostatectomy, bilateral orchiectomy, and estrogen therapy for advanced prostatic cancer, 313
combined with methotrexate and CCNU (CMC) in the treatment of small cell lung carcinoma, 349
combined with radiation, effect of sequence of regimens on murine osteosarcoma, 1569
combined with 6-thioguanine, cytosine arabinoside, and methyl-CCNU (TEAM) in the treatment of refractory acute leukemia, 1397
combined with vincristine, adriamycin, methotrexate, and citrovorum factor rescue in the treatment of metastatic breast cancer, phase II study, 1527
combined with vincristine and prednisone in the treatment of stage IV non-Hodgkin's lymphomas, 1117
combined with vincristine and prednisone or with vincristine, prednisone, and BCNU in non-Hodgkin's lymphoma, 1085
combined with vincristine, methotrexate, citrovorum factor rescue, and cytosine arabinoside in the treatment of diffuse histiocytic lymphoma, 1109
combined with vincristine, methyl-CCNU, and bleomycin in the treatment of advanced lung carcinoma, 59
effects of treatment with, on hormone-dependent and hormone-independent tumor cells in transplanted GR mouse mammary tumors, 861
evaluation of a MOPP-type regimen in histiocytosis X, 855
and 5-FU infusion in the treatment of advanced ovarian cancer, 1573
given alone continuously or given continuously with methotrexate, 5-FU, vincristine, and prednisone given intermittently in the treatment of advanced breast cancer, 47
high-dose, treatment of advanced ovarian cancer with, after failure on melphalan, 1369
L2 protocol: combination chemotherapeutic regimen for treatment of advanced non-Hodgkin's lymphoma, 7
passive immunotherapy for mouse leukemias with antisera of "directed" specificity: synergism with the action of, 1499
phase II study, combined with *cis*-dichlorodiammineplatinum(II) and adriamycin or with VP-16-213 in the treatment of small cell lung cancer, 93
and procarbazine, vincristine, and CCNU combined with radiation therapy in the treatment of extensive oat cell lung cancer, 1427
pulmonary metastases of the Lewis lung tumor—cell kinetics and response to, at different sizes, 29
used in combination immunochemotherapy of oat cell carcinoma of the lung, 343
with vincristine and methotrexate followed by radiation for oat cell carcinoma of the lung, 1
with vincristine and prednisone in the treatment of non-Hodgkin's lymphoma, 1079
Cytomegalovirus, in vitro transformation of human cells, 139
Cytosine arabinoside (NSC-63878)
combined with adriamycin in the treatment of adult acute myelocytic leukemia, 89
combined with cyclophosphamide, vincristine, methotrexate, and citrovorum factor rescue in the treatment of diffuse histiocytic lymphoma, 1109
combined with 6-thioguanine, cyclophosphamide, and methyl-CCNU (TEAM) in the treatment of refractory acute leukemia, 1397
concentration in brain after ventriculocisternal perfusion, 625
and daunorubicin in the treatment of adult acute nonlymphocytic leukemia, 1441
distribution of, and its products in mice, dogs, and monkeys and effect of tetrahydrouridine, 395
extraction and analytic procedures for, and its mono-, di-, and tri-phosphates, 643
with methotrexate via Ommaya reservoir in the treatment of meningeal neoplasms, 733
microbiologic assay for, 591 and 597
phase II study of, in the treatment of advanced large bowel cancer, 1725
physiologic disposition and effect of tetrahydrouridine upon deamination of, in man, 1347
physiologic disposition of, and its derivatives, in man, 723
potential advances in the clinical use of, 717
in the prophylaxis and treatment of central nervous system leukemia, 661
and tetrahydrouridine in mouse tumors, 1355
in the treatment of multiple myeloma in remission, 381

D

Daunorubicin (NSC-82151)
and cytosine arabinoside in the treatment of adult acute nonlymphocytic leukemia, 1441
hypothesis concerning possible new derivatives of, with enhanced DNA-binding properties, 928
time relationship between last dose of, and congestive heart failure, 1411
DDEP *see* Pyrimidine, 2,4-diamino-5-(3,4-dichlorophenyl)-6-methyl-, 6-ethyl analog
DDMP *see* Pyrimidine, 2,4-diamino-5-(3,4-dichlorophenyl)-6-methyl-
Dehydroemetine (NSC-129414), used in combination immunochemotherapy of oat cell carcinoma of the lung, 343
4-Demethoxydaunorubicin (NSC-256439), oral, antitumor activity of, in animals, 893

β-2′-Deoxythioguanosine (NSC-71261)
combined with 5-azacytidine in adult acute leukemia, 915
phase II study of, in adult acute leukemia, 1379

Diabetes mellitus *see* Adverse effects in man

Dianhydrogalactitol (NSC-132313)
combined with ICRF-159 in a phase II study in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy, 81
labeled, uptake of, into human gliomas and nervous tissue, 841
versus platinum-based polychemotherapy in advanced non-small cell lung cancer, 1339

Dichloro(1,2-diaminocyclohexane)platinum(II) (NSC-194814), preparation and antitumor evaluation of water-soluble derivatives of, 1519

cis-Dichlorodiammineplatinum(II) (NSC-119875)
clinical response and toxicity with, in children, 835
combined with adriamycin in patients with advanced cancer, 869
combined with adriamycin in the treatment of various human tumors, 477
high-dose, with forced diuresis, phase I study of, 367
modification of the renal toxicity of, using furosemide in male F344 rats, 375
phase II study, combined with adriamycin and cyclophosphamide in the treatment of small cell lung cancer, 93
platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer, 1339
in the treatment of epidermoid carcinoma of the head and neck, 359

Diethylstilbestrol (NSC-3070), alone, combined with cyclophosphamide, or combined with estramustine phosphate in the treatment of prostatic cancer, 317

Dimethylsulfoxide (NSC-763), effect of, on tumor control and skin tolerance in the rat, 825

^{99m}Tc Diphosphate bone scan, implications of, for the treatment of primary breast cancer, 1249

DMSO *see* Dimethylsulfoxide

Drug interactions, with antineoplastic agents, 1231

DTIC (NSC-45388)
combined with adriamycin and cyclophosphamide in the treatment of advanced small cell lung cancer, 481
combined with adriamycin: high incidence of cardiomyopathy in children treated with, 1736
combined with vincristine and methyl-CCNU in the treatment of disseminated malignant melanoma, 881
possible neurologic complication of, 105
in the treatment of prostatic cancer, 317
use of, in the management of carcinoid syndrome, 101
use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to, 1738

Dunn osteosarcoma *see* Tumor systems in animals

Dunning R3327H prostatic adenocarcinoma *see* Tumor systems in animals

E

Electron microscopy
scanning and transmission, morphologic and immunologic studies of human prostatic carcinoma cells, 133
scanning, in the study of prostatic cancer, 227
used to detect and characterize oncornaviruses in human prostatic carcinoma cells, 119

Epipodophyllotoxins *see* VM-26, VP-16-213

Estracyt *see* Estramustine phosphate

Estramustine phosphate (NSC-89199)
alone, combined with diethylstilbestrol, combined with Leo 1031, or combined with cyclophosphamide in the treatment of prostatic cancer, 317
alone or combined with Leo 1031 in the treatment of prostatic cancer, 307
effect on Dunning R3327H prostatic adenocarcinoma in rats, 273

Etoprine *see* Pyrimidine, 2,4-diamino-5-(3,4-dichlorophenyl)-6-methyl-, 6-ethyl analog

F

5-Fluorouracil (NSC-19893; 5-FU)
and adriamycin in the treatment of advanced hepatoma, 1595
as chemotherapy for metastatic carcinoid tumors, 1699
combined with cyclophosphamide, radical retropubic prostatectomy, bilateral orchiectomy, and estrogen therapy for advanced prostatic cancer, 313
combined with hexamethylmelamine in the treatment of advanced ovarian cancer, 1691
combined with methotrexate and used after cyclophosphamide and adriamycin induction in metastatic breast cancer, 1685
combined with methyl-CCNU versus methyl-CCNU alone in the treatment of large bowel cancer, 1453
combined with procarbazine in the treatment of metastatic melanoma, 1709
compared to adriamycin in advanced prostatic cancer, 325
with cyclophosphamide, methotrexate, vincristine, and prednisone in the treatment of advanced breast cancer, 47
enhancement of antileukemic effect in L1210 leukemia with the combination of OK-432 and, 17
-induced increase of total serum thyroxine and triiodothyronine levels in patients with advanced breast cancer, 1291
infusion and cyclophosphamide in the treatment of advanced ovarian cancer, 1573
microbiologic assay for, 597
phase II trial of ftorafur in patients with colorectal cancer refractory to, 1579
and streptozotocin in the treatment of metastatic gastrointestinal neoplasms, 1375
in the treatment of childhood solid tumors, 69
in the treatment of prostatic cancer, 317
versus CCNU in the treatment of metastatic prostatic cancer, 1589

Folate metabolism, regulatory control of tetrahydrofolate coenzymes in folate auxotrophs, 533
Folic acid, microbiologic assay for, 597
Ftorafur (NSC-148958)
intermittent high single-dose, phase I clinical trial with a pharmacologic-toxicity correlation, 1495
and iv methyl-CCNU with or without methanol-extracted residue of bacillus Calmette-Guérin for metastatic adenocarcinoma of the colon, 1581
phase I trial of, combined with mitomycin C or methyl-CCNU in gastrointestinal cancers, 463
phase II clinical trial of, in 5-FU-refractory colorectal cancer, 1579
Furosemide (NSC-269420), modification of the renal toxicity of *cis*-dichlorodiammineplatinum(II) with, in male F344 rats, 375

G

Gastrointestinal cancer *see* Cancer, gastrointestinal
Geldanamycin (NSC-122750), and its derivatives, effects of, on RNA-directed DNA polymerase and infectivity of Rauscher leukemia virus, 815
Germ-cell tumors *see* Cancer, testicular
Glioma (*see also* Cancer, brain)
human, uptake of labeled dianhydrogalactitol into, 841
malignant, high-dose methotrexate in the treatment of, 753
GR mouse mammary tumor *see* Tumor systems in animals
Gross leukemia *see* Tumor systems in animals

H

Head and neck cancer *see* Cancer, head and neck
Hemodialysis, role for, in the carcinoid syndrome, 107
Heparin, and polychemotherapy in the treatment of lung cancer, 1399
Hepatocellular cancer *see* Cancer, hepatocellular
Hepatoma, advanced, adriamycin and 5-FU in the treatment of, 1595
Hepatoma cell lines *see* Tumor systems in animals
Hexamethylmelamine (NSC-13875)
combined with 5-FU in the treatment of advanced ovarian cancer, 1691
combined with vincristine and methotrexate in advanced neoplasms, 919
regression of human lung tumor xenografts induced by water-soluble analogs of, 927
Histiocytosis X, evaluation of a MOPP-type regimen in, 855
Hodgkin's disease
advanced, combined chemotherapy (MOPP or ABVD)-radiotherapy approach in, 769
disseminated, primary treatment of, with BCNU alone and in combination with vincristine, procarbazine, and prednisone, 789
phase II trial of piperazinedione in the treatment of, 1617
HT 67 transplantable mouse tumor *see* Tumor systems in animals
Hydroxyurea (NSC-32065)
compared to ICRF-159 and melphalan in metastatic prostatic cancer, 311
in the treatment of multiple myeloma in remission, 381
Hypotension *see* Adverse effects in man

I

ICRF-159 (NSC-129943)
combined with dianhydrogalactitol in a phase II study in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy, 81
compared to melphalan and hydroxyurea in metastatic prostatic cancer, 311
Immunochemotherapy, in oat cell carcinoma of the lung, 343
Immunotherapy (*see also Corynebacterium parvum*, Bacillus Calmette-Guérin, Methanol extraction residue of bacillus Calmette-Guérin), passive, for mouse leukemias with antisera of "directed" specificity: synergism with the action of cyclophosphamide, 1499

J

Jatrophone, a new plant-derived tumor inhibitor, mechanism of action, 1115
JB-1 ascites tumor *see* Tumor systems in animals

L

Laminar air flow rooms, necessity for, during intensive chemotherapy for small cell lung carcinoma, 349
Laparotomy, and clinical evaluation of patients with non-Hodgkin's lymphomas, 981
Large bowel cancer *see* Cancer, large bowel
Leo 1031 (NSC-134087; prednimustine)
alone or combined with estramustine phosphate in prostatic cancer, 317
in the treatment of prostatic cancer, 307
Leptomeningeal neoplasms *see* Meningeal neoplasms
Leucovorin *see* Citrovorum factor
Leukemia
acute
adult, combination therapy with 5-azacytidine and β-2′-deoxythioguanosine in, 915
adult, evaluation of radiotherapy for localized inflammatory skin and perianal lesions: a prospectively randomized double blind study, 1301
adult, phase II study of β-2′-deoxythioguanosine in, 1379
adult, previously treated, adriamycin therapy in, 905
central nervous system, antimetabolites in the prophylaxis and treatment of, 661
lymphocytic
childhood, late-stage, phase II trial of asaley in, 1373

high-dose methotrexate in, 727
mode of decrease of leukemic cells and leukocytes during neocarzinostatin treatment, 73
myelocytic, in adults, adriamycin and cytosine arabinoside in the treatment of, 89
myelogenous, potential advances in the clinical use of cytosine arabinoside, 717
nonlymphocytic
adult, daunorubicin and cytosine arabinoside in the treatment of, 1441
adult refractory, treatment of, with sc 5-azacytidine, 1721
natural resistance to methotrexate in, 667
vinblastine, 5-azacytidine, and VP-16-213 in the treatment of previously treated patients with, 1599
refractory, treatment of, with high-dose chemotherapy, 1397
chronic, myeloid, treatment of, with repeated single doses of busulfan, 43
Lewis lung carcinoma *see* Tumor systems in animals
Ligand-binding radioassay, for the antifolate compounds: application in patients receiving methotrexate, 575
L1210 leukemia *see* Tumor systems in animals
L2 protocol (6-thioguanine, vincristine, daunorubicin, methotrexate, cytosine arabinoside, prednisone, L-asparaginase, BCNU, and cyclophosphamide), used for advanced non-Hodgkin's lymphoma, 7
Lukes-Collins classification, its significance in staging lymphomas, 971
Lung cancer *see* Cancer, lung
T-Lymphocyte-deficient mice, chemotherapy of human tumors in, 451
Lymphoid cells, human, lethal and kinetic response to melphalan, 425
Lymphoma (*see also* Hodgkin's disease)
advanced lymphocytic, randomized comparisons of chemotherapy and radiotherapy alone or in combination, 1153
advanced, malignant, pilot study of 2 adriamycin-based regimens in patients with, 65
diffuse histiocytic, cyclophosphamide, vincristine, methotrexate, citrovorum factor rescue, and cytosine arabinoside in the treatment of, 1109
Lukes-Collins classification and its significance, 971
lymphocytic, total-body irradiation in the treatment of, 1149
malignant, combined modality therapy for, 1199
malignant, functional markers: a new perspective on, 953
non-Hodgkin's
adult, prognostic significance of lymphocytic surface markers and histology in, 963
advanced, cyclophosphamide L2 protocol in the treatment of, 7
central nervous system, use of weekly methotrexate and citrovorum factor rescue in, 695
chemotherapy of: the Stanford experience, 1049
chemotherapy of: 10 years' experience in the Southwest Oncology Group, 1067
childhood, management of, 1161
childhood, role of staging in, 1001
clinical and surgical (laparotomy) evaluation of patients with, 981
combination chemotherapy in: results of long-term followup, 1057
curability of, 1185
current cooperative clinical trials, 1191
cyclophosphamide, vincristine, and prednisone with and without BCNU in the treatment of, 1085
histiocytic, comparison of nodal primary versus extranodal primary, 999
histopathologic classification of, 1037
immunologic classification of: current status, 1179
localized, radiation therapy for, 1129
new approaches to the treatment of, 1209
pathology of: new classifications, 945
peritoneoscopy used to evaluate therapeutic efficacy in, 1017
phase II trial of piperazinedione in the treatment of, 1617
prednisone in addition to cyclophosphamide and vincristine in the treatment of: Eastern Cooperative Oncology Group experience, 1079
Rappaport classification of: histologic features and clinical significance, 935
sequential staging in, 993
stage III and IV, overview of four clinical studies of chemotherapy by the Cancer and Leukemia Group B, 1097
stage IV, non-cross-resistant combinations (cyclophosphamide, vincristine, and prednisone; adriamycin, bleomycin, and prednisone) in, 1117
systematic re-staging in the management of, 1009
team approach to the management of, 1137
validity of the Ann Arbor staging classification, 1023

M

Madison 109 lung carcinoma *see* Tumor systems in animals
MA-21224 transplantable mammary carcinoma *see* Tumor systems in animals
Maytansine (NSC-153858), acute toxicity of, in F344 rats, 1333
MEA *see* Mercaptoethylamine
Mechlorethamine (NSC-762)
combined with adriamycin and CCNU (NAC) and compared to bleomycin, adriamycin, CCNU, vincristine, and mechlorethamine (BACON) in the treatment of squamous lung cancer, 1623
combined with procarbazine, central nervous system disturbances after, 1713
Medroxyprogesterone acetate (NSC-26386), for the treatment of metastatic and recurrent ovarian carcinoma, 913
Melanoma
advanced malignant, resistant to DTIC, use of methyl-CCNU and procarbazine in, 1738
disseminated malignant, DTIC, vincristine, and methyl-CCNU in the treatment of, 881
malignant, phase II trial of pyrazofurin in, 1733
metastatic, 5-FU combined with procarbazine in the treatment of, 1709

metastatic, phase I study of high-dose *cis*-dichlorodiammineplatinum(II) with forced diuresis, 367
Melphalan (NSC-8806)
in advanced prostatic cancer: a pilot study, 923
plus adriamycin versus adriamycin alone in the treatment of advanced ovarian carcinoma, 355
combined with CCNU, methotrexate, and prednisone (CAMP) in the treatment of advanced breast cancer, 1603
compared to ICRF-159 and hydroxyurea in metastatic prostatic cancer, 311
lethal and kinetic response of cultured human lymphoid cells to, 425
pharmacokinetics of the absorption, distribution, and elimination of, in the dog, 1637
treatment of advanced ovarian cancer with high-dose cyclophosphamide after failure on, 1369
Meningeal neoplasms
malignant, treatment of, with intrathecal thioTEPA: a phase II study, 885
treatment of, with methotrexate with or without cytosine arabinoside via Ommaya reservoir, 733
Mercaptoethylamine (NSC-25116), effect of, on tumor control and skin tolerance in the rat, 825
6-Mercaptopurine (NSC-755), microbiologic assay for, 597
Methanol extraction residue of bacillus Calmette-Guérin
combined with iv methyl-CCNU and ftorafur for metastatic adenocarcinoma of the colon, 1581
phase I study of, 471
preclinical study of iv administration of, 901
Methotrexate (NSC-740)
and citrovorum factor rescue given weekly: effect of alkalinization on nephrotoxicity; pharmacokinetics in the central nervous system; and use in central nervous system non-Hodgkin's lymphoma, 695
and citrovorum factor rescue in the management of brain tumors, 691
with citrovorum factor rescue in the treatment of central nervous system tumors in children, 681
with citrovorum factor in the treatment of osteogenic sarcoma, 675
combined with CCNU, melphalan, and prednisone (CAMP) in the treatment of advanced breast cancer, 1603
combined with citrovorum factor, in the treatment of alveolar soft part sarcoma, 77
combined with citrovorum factor rescue, cyclophosphamide, vincristine, and cytosine arabinoside in the treatment of diffuse histiocytic lymphoma, 1109
combined with citrovorum factor rescue, vincristine, adriamycin, and cyclophosphamide in the treatment of metastatic breast cancer, phase II study, 1527
combined with cyclophosphamide and CCNU (CMC) in the treatment of small cell lung cancer, 349
combined with 5-FU and used after cyclophosphamide and adriamycin induction in metastatic breast cancer, 1685
combined with methyl-CCNU in patients with advanced neoplastic diseases, phase I trial, 889
combined with vincristine and hexamethylmelamine in advanced neoplasms, 919
compounds altering the activity of, 1231
concentration in brain after ventriculocisternal perfusion, 625
with cyclophosphamide, 5-FU, vincristine, and prednisone in the treatment of advanced breast cancer, 47
with cyclophosphamide and vincristine followed by radiation for oat cell carcinoma of the lung, 1
with or without cytosine arabinoside via Ommaya reservoir in the treatment of meningeal neoplasms, 733
distribution of, in the cerebrospinal fluid and brain after intraventricular administration, 633
dose-dependent metabolism of, in man and rhesus monkeys, 651
effect of, on cellular metabolism: some critical elements in the drug-cell interaction, 649
effect of, versus enzymatic folate depletion on folate and thymidine enzymes in cultured mammalian cells, 539
high-dose, changes in glomerular filtration rate associated with, in adults, 1389
high-dose, and citrovorum factor administration, incidence of drug-related deaths secondary to, 745
high-dose, in acute lymphocytic leukemia, 727
high-dose, in the treatment of malignant gliomas, 753
high-dose, recovery from toxicity associated with: prognostic factors, 797
high-dose therapy, with citrovorum factor: a pharmacologic perspective in murine tumor models, 565
high-dose with citrovorum factor rescue, pharmacokinetics of, 1665
high-dose, with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity, 779
intrathecal, clinical pharmacology of: an improved dosage regimen derived from age-related pharmacokinetics, 1419
intrathecal, clinical pharmacology of; pharmacokinetics in nontoxic patients after lumbar injection, 703
kinetics of elimination of, from cerebrospinal fluid space of monkeys after ventriculolumbar perfusion, 603
ligand-binding radioassay for: application in patients receiving, 575
microbiologic assay for, 597
microbiologic disc assay for 5-methyltetrahydrofolate in the presence of, 1657
natural resistance to, in human acute nonlymphocytic leukemia, 667
new "rescue" with massive doses of citrovorum factor for potentially lethal toxicity of, 749
observations on the human pharmacology of, 1647
perilymph penetration of, in cats, 613
plasma-methotrexate levels, effect of hydration on, 1393
radioimmunoassay for, 585
removal of, by filtration-adsorption using charcoal filters or by hemodialysis, 751
reversal of toxicity, in rodents, 647
role of drug concentration, duration of exposure, and endogenous metabolites in determining cytotoxicity of, 709
selective protection of the gastrointestinal tract against, in patients with trophoblastic tumors, 895
in the treatment and prophylaxis of central nervous system leukemia, 661

in the treatment of central nervous system tumors, 657
used in combination immunochemotherapy of oat cell carcinoma of the lung, 343
Methyl-CCNU (NSC-95441)
alone versus combination with 5-FU in the treatment of large bowel cancer, 1453
combined with cyclophosphamide, vincristine, and bleomycin in the treatment of advanced lung carcinoma, 59
combined with DTIC and vincristine in the treatment of disseminated malignant melanoma, 881
combined with methotrexate in patients with advanced neoplastic diseases: phase I trial, 889
combined with procarbazine for advanced malignant melanoma resistant to DTIC therapy, 1738
combined with 6-thioguanine, cyclophosphamide, and cytosine arabinoside (TEAM) in the treatment of refractory acute leukemia, 1397
iv and ftorafur with or without methanol-extracted residue of bacillus Calmette-Guérin for metastatic adenocarcinoma of the colon, 1581
iv, combined with VM-26 and cranial irradiation in the therapy for malignant brain tumors, 1715
iv, unexpected pain syndrome during a phase I study of, 1413
oral, phase II study of, with prednisone in previously treated alkylating agent-resistant multiple myeloma, 785
phase II study in patients with previously treated metastatic neuroblastoma, 83
phase I trial, combined with ftorafur in gastrointestinal cancers, 463
qualitative and quantitative toxicity of sublethal doses of, in BDF mice, 409
in the treatment of mustard-resistant ovarian adenocarcinoma, 1533
Methylprednisolone (NSC-19987), combined with CCNU and bleomycin with or without adriamycin in the treatment of renal cell carcinoma, 1591
5-Methyltetrahydrofolate
microbiologic assay for, 597
microbiologic disc assay for, in the presence of methotrexate, 1657
Metoprine *see* Pyrimidine, 2,4-diamino-5-(3,4-dichlorophenyl)-6-methyl-
Microbiologic assays
for antimetabolites, 591
for cancer chemotherapeutic agents, 597
Mitomycin C (NSC-26980), phase I trial of, combined with ftorafur in gastrointestinal cancers, 463
MOPP (mechlorethamine, vincristine, prednisone, and procarbazine)
or ABVD combined with radiotherapy in advanced Hodgkin's disease, 769
evaluation of a MOPP-type regimen in histiocytosis X, 855
Murine myeloid leukemia *see* Tumor systems in animals
Murine sarcoma virus-induced rhabdomyosarcoma *see* Tumor systems in animals
Myeloma
multiple, phase II trial of piperazinedione in the treatment of, 1617
multiple, in remission, treatment of, with azathioprine, cytosine arabinoside, hydroxyurea, or vincristine, drugs having cell cycle specific characteristics, 381
previously treated alkylating agent-resistant multiple, phase II study of oral methyl-CCNU and prednisone in, 785
Myelosarcoma, suppression of human cell growth in athymic mice by a primate antiserum, 1679

N

NAC (mechlorethamine, adriamycin, and CCNU), compared to bleomycin, adriamycin, CCNU, vincristine, and mechlorethamine (BACON) for extensive squamous lung carcinoma, 1623
Neocarzinostatin (NSC-157365)
mode of decrease of leukemic cells and leukocytes during treatment with, 73
radioimmunoassay for, 585
Neuroblastoma
childhood, VM-26 in the treatment of, 1243
previously treated, methyl-CCNU for patients with, a phase II study, 83
Nitrosoureas *see* BCNU, CCNU, Methyl-CCNU, 4-(3-(2-Chloroethyl)-3-nitrosoureido)-*cis*-cyclohexanecarboxylic acid, Streptozotocin
Non-Hodgkin's lymphoma *see* Lymphoma, non-Hodgkin's
Novikoff hepatoma *see* Tumor systems in animals
NSC-740 *see* Methotrexate
NSC-750 *see* Busulfan
NSC-752 *see* 6-Thioguanine
NSC-762 *see* Mechlorethamine
NSC-763 *see* Dimethylsulfoxide
NSC-1026 *see* Cycloleucine
NSC-1149 *see* *p*-Chlorophenoxyisobutyric acid
NSC-3053 *see* Actinomycin D
NSC-3070 *see* Diethylstilbestrol
NSC-3088 *see* Chlorambucil
NSC-3590 *see* Citrovorum factor
NSC-6396 *see* ThioTEPA
NSC-8769 *see* *p*-Chlorophenoxyacetic acid
NSC-8806 *see* Melphalan
NSC-10023 *see* Prednisone
NSC-13875 *see* Hexamethylmelamine
NSC-18429 *see* Aniline mustard
NSC-19494 *see* Pyrimidine, 2,4-diamino-5-(3,4-dichlorophenyl)-6-methyl-
NSC-19893 *see* 5-Fluorouracil
NSC-19987 *see* Methylprednisolone
NSC-25116 *see* Mercaptoethylamine
NSC-26271 *see* Cyclophosphamide
NSC-26386 *see* Medroxyprogesterone acetate
NSC-26980 *see* Mitomycin C
NSC-32065 *see* Hydroxyurea
NSC-39084 *see* Azathioprine
NSC-45388 *see* DTIC
NSC-49842 *see* Vinblastine
NSC-56654 *see* Azotomycin
NSC-63878 *see* Cytosine arabinoside
NSC-67574 *see* Vincristine
NSC-68928 *see* 1-β-D-Arabinofuranosyluracil
NSC-71261 *see* β-2'-Deoxythioguanosine

NSC-71964 *see* [*p*-[Bis(2-chloroethyl)amino]phenyl]acetic acid
NSC-77213 *see* Procarbazine
NSC-79037 *see* CCNU
NSC-85998 *see* Streptozotocin
NSC-88536 *see* Calusterone
NSC-89199 *see* Estramustine phosphate
NSC-95441 *see* Methyl-CCNU
NSC-102816 *see* 5-Azacytidine
NSC-109229 *see* L-Asparaginase
NSC-111071 *see* Carbenicillin
NSC-112907 *see* Tetrahydrouridine
NSC-119875 *see* *cis*-Dichlorodiammineplatinum(II)
NSC-122750 *see* Geldanamycin
NSC-122819 *see* VM-26
NSC-123127 *see* Adriamycin
NSC-125066 *see* Bleomycin
NSC-129414 *see* Dehydroemetine
NSC-129943 *see* ICRF-159
NSC-132313 *see* Dianhydrogalactitol
NSC-134087 *see* Leo 1031
NSC-139105 *see* Triazinate
NSC-141540 *see* VP-16-213
NSC-143095 *see* Pyrazofurin
NSC-143647 *see* DL-Alanosine
NSC-145668 *see* Cyclocytidine
NSC-148958 *see* Ftorafur
NSC-153174 *see* 4-(3-(2-Chloroethyl)-3-nitrosoureido)-*cis*-cyclohexanecarboxylic acid
NSC-153858 *see* Maytansine
NSC-157365 *see* Neocarzinostatin
NSC-166641 *see* 2,2′-Anhydro-1-β-D-arabinofuranosyl-5-fluorocytosine
NSC-167780 *see* Asaley
NSC-177001 *see* Amikacin
NSC-177391 *see* *meso*-Tetra(*p*-sulfophenyl)porphine
NSC-180024 *see* Carminomycin
NSC-180973 *see* Tamoxifen
NSC-194814 *see* Dichloro(1,2-diaminocyclohexane)-platinum(II)
NSC-245467 *see* Vindesine sulfate
NSC-256439 *see* 4-Demethoxydaunorubicin
NSC-269420 *see* Furosemide
NSC-402815 *see* OK-432
NSC-409962 *see* BCNU
NSC-529180 *see* 1-β-D-Arabinofuranosyl-5-fluorocytosine
NSC-529861 *see* Chlorasquin
Nude mice *see* Athymic mice

O

Oat cell cancer *see* Cancer, lung
OK-432 (NSC-402815), enhancement of antileukemic effect in L1210 leukemia with the combination of 5-FU and, 17
Ommaya reservoir, treatment of meningeal tumors with methotrexate with or without cytosine arabinoside via, 733
Oncornaviruses
role of, in carcinoma of the prostate, 131
search for, in human prostatic cancer, 119
Ovarian cancer *see* Cancer, ovarian

P

P-30 antigen, in mouse prostate, 129
β-Peltatin *A*-α-L-arabinofuranoside, selective tumor DNA synthesis inhibition: in vivo prodrug activation by an exogenous enzyme, 1489
Peptichemio, antitumor effects of, in animals, 473
Pericardial tamponade, prostatic carcinoma presenting as, 1607
Peritoneoscopy, a technique to evaluate therapeutic efficacy in non-Hodgkin's lymphoma patients, 1017
Phase I studies
of carminomycin in soft tissue sarcomas, 1705
of combination methotrexate and methyl-CCNU in patients with advanced neoplastic diseases, 889
of ftorafur combined with mitomycin C or methyl-CCNU in gastrointestinal cancers, 463
of high-dose *cis*-dichlorodiammineplatinum(II) with forced diuresis, 367
of immunotherapy with methanol extraction residue of bacillus Calmette-Guérin, 471
intermittent high single-dose ftorafur: clinical trial with a pharmacologic-toxicity correlation, 1495
of iv methyl-CCNU, unexpected pain syndrome during, 1413
and phase II study of cyclocytidine, 437
Phase II studies
of asaley in children with late-stage acute lymphocytic leukemia, 1373
of 5-azacytidine in solid tumors, 51, 55
of azotomycin in sarcomas, 1719
of Baker's antifol in metastatic sarcoma, 1485
of β-2′-deoxythioguanosine in adult acute leukemia, 1379
of bleomycin, CCNU, and streptozotocin in patients with metastatic breast cancer, 1365
of cytosine arabinoside in advanced large bowel cancer, 1725
of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy, 81
of ftorafur in 5-FU-refractory colorectal cancer, 1579
of intrathecal thioTEPA in malignant meningeal disease, 885
of methyl-CCNU for patients with previously treated metastatic neuroblastoma, 83
of oral methyl-CCNU and prednisone in previously treated alkylating agent-resistant multiple myeloma, 785
and phase I study of cyclocytidine, 437
of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma, 1617
of piperazinedione in metastatic breast cancer, 1711
of polychemotherapy regimens in small cell lung cancer, 93
of pyrazofurin in advanced colorectal carcinoma, 491
of pyrazofurin in malignant melanoma, 1733
of twice weekly 5-azacytidine infusion in the treatment of disseminated metastatic cancer, 1675
of vincristine, adriamycin, cyclophosphamide, methotrexate, and citrovorum factor rescue in the treatment of metastatic breast cancer, 1527

of vindesine sulfate in the therapy for advanced renal carcinoma, 1727
of weekly administration of VP-16-213 in small cell lung carcinoma, 489
Piperazinedione (NSC-135758)
phase II study of, in the treatment of metastatic breast carcinoma, 1711
phase II trial of, in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma, 1617
in the treatment of metastatic renal cancer, 1731
Platinum compounds [*see also cis*-dichlorodiammineplatinum(II)]
chemotherapy of advanced L1210 leukemia with platinum compounds in combination with other antitumor agents, 445
preparation and antitumor evaluation of water-soluble derivatives of dichloro(1,2-diaminocyclohexane)-platinum(II), 1519
P388 leukemia *see* Tumor systems in animals
POCC (procarbazine, vincristine, cyclophosphamide, and CCNU), followed by radiation and compared to cyclophosphamide, methotrexate, and vincristine followed by radiation in the treatment of oat cell carcinoma of the lung, 1
Polyaminoaryl nitrile, substituted, activation by gamma irradiation, in vitro and in vivo studies, 419
Prednimustine *see* Leo 1031
Prednisone (NSC-10023)
with CCNU, vincristine, and cyclophosphamide followed by radiation for oat cell carcinoma of the lung, 1
combined with CCNU, melphalan, and methotrexate (CAMP) in the treatment of advanced breast cancer, 1603
combined with cyclophosphamide and vincristine or adriamycin and bleomycin in the treatment of stage IV non-Hodgkin's lymphomas, 1117
combined with cyclophosphamide and vincristine or with cyclophosphamide, vincristine, and BCNU in non-Hodgkin's lymphoma, 1085
combined with vincristine, procarbazine, and BCNU in the primary treatment of disseminated Hodgkin's disease, 789
with cyclophosphamide and vincristine in the treatment of non-Hodgkin's lymphoma, 1079
with cyclophosphamide, methotrexate, 5-FU, and vincristine in the treatment of advanced breast cancer, 47
distribution and metabolism of, in mice, dogs, and monkeys, 1279
phase II study of, with methyl-CCNU in previously treated alkylating agent-resistant multiple myeloma, 785
Procarbazine (NSC-77213)
combined with adriamycin and vincristine in previously treated patients with small cell lung carcinoma, 485
combined with 5-FU in the treatment of metastatic melanoma, 1709
combined with mechlorethamine, central nervous system disturbances after, 1713
combined with methyl-CCNU for advanced melanoma resistant to DTIC therapy, 1738
combined with vincristine, prednisone, and BCNU in the primary treatment of disseminated Hodgkin's disease, 789
in the treatment of prostatic cancer, 317
and vincristine, cyclophosphamide, and CCNU combined with radiotherapy in the treatment of extensive oat cell lung cancer, 1427
Prodrug activation, in vivo, by an exogenous enzyme: selective tumor DNA synthesis inhibition, 1489
Prostate cancer *see* Cancer, prostate
Prostate, rats, as an immunologically privileged site, 217
Prostatic acid phosphatase
immunochemical studies of, 201
new agents for prostatic cancer activated specifically by, 259
study of isoenzyme patterns of, in patient serum: potential value in the diagnosis of prostatic cancer, 193
Prostatic cells
characteristics of human cell cultures, 147
culture of mammalian cells, 161
human, morphologic and immunologic studies in, 133
human normal, hyperplastic and neoplastic, RNA tumor virus-like activities in: possible novel pharmacologic approaches, 113
human normal, hyperplastic and neoplastic, separation and characterization of epithelial cells from prostates and prostatic carcinomas, 157
human, search for oncogenic viruses in, 119
in vitro transformation of human cells in culture, 139
P-30 antigen in mouse, 129
role of oncornaviruses in prostatic carcinoma tissue in culture, 131
Pyrazofurin (NSC-143095)
initial clinical study with, 389
phase II study of, in advanced colorectal carcinoma, 491
phase II trial in malignant melanoma, 1733
Pyrimidine, 2,4-diamino-5-(3,4-dichlorophenyl)-6-methyl- (DDMP; NSC-19494)
alone and combined with citrovorum factor, toxicity and responsiveness of ascitic, solid, and intracranial Sarcoma 180 to, 1325
6-ethyl analog of (DDEP, etoprine), lipid-soluble diaminopyrimidine inhibitor of dihydrofolate reductase, pharmacokinetic evaluation of, 559
lipid-soluble diaminopyrimidine inhibitor of dihydrofolate reductase, pharmacokinetic evaluation of, 559

R

Radiation, ionizing, in vitro and in vivo studies of drug activation by, 419
Radiation therapy
with adriamycin and cyclophosphamide for the treatment of carcinoma of the lung, 875
after treatment with procarbazine, vincristine, cyclophosphamide, and CCNU in extensive oat cell lung cancer, 1427
combined with chemotherapy in malignant lymphomas, 1199

combined with chemotherapy (MOPP or ABVD) in advanced Hodgkin's disease, 769
combined with cyclophosphamide, effect of sequence of regimens on murine osteosarcoma, 1569
combined with procarbazine, vincristine, cyclophosphamide, and CCNU, or cyclophosphamide, vincristine, and methotrexate in the treatment of oat cell carcinoma of the lung: a randomized trial, 1
cranial, combined with iv methyl-CCNU and VM-26 in the therapy for malignant brain tumors, 1715
effect of radioprotective drugs MEA, DMSO, and WR-2721 on tumor control and skin tolerance in the rat, 325
evaluation of, for localized inflammatory skin and perianal lesions in adult leukemia: a prospectively randomized double blind study, 1301
extended-field, evaluation of, for prostatic neoplasm, 297
interstitial, of cancer of the prostate using iridium 192 wires, 329
of localized non-Hodgkin's lymphoma, 1129
randomized comparisons of, alone or in combination with chemotherapy in advanced lymphocytic lymphoma, 1153
total-body, for lymphocytic lymphoma, 1149
Radioimmunoassays, for methotrexate, citrovorum factor, neocarzinostatin, and actinomycin D, 585
Radioprotective drugs, effect of MEA, DMSO, and WR-2721 on tumor control and skin tolerance in the rat, 825
Rappaport classification, of non-Hodgkin's lymphoma: histologic features and clinical significance, 935
Rauscher leukemia virus, effects of geldanamycin and its derivatives on RNA-directed DNA polymerase and infectivity of, 815
Raynaud's phenomenon *see* Adverse effects in man
Renal cancer *see* Cancer, renal
RFM mouse myeloid leukemia *see* Tumor systems in animals

S

Sarcoma
alveolar soft part, chemotherapy of, 77
metastatic osteogenic, actinomycin D in the treatment of, 498
metastatic, phase II trial of Baker's antifol in, 1485
osteogenic, high-dose methotrexate with citrovorum factor in, 675
phase II study of azotomycin in, 1719
soft tissue, phase I study of carminomycin in, 1705
Sarcoma 180 *see* Tumor systems in animals
Sarcoma 180 Japan *see* Tumor systems in animals
Sarcoma T241 *see* Tumor systems in animals
Spindle poisons, new agents for prostatic cancer activated specifically by prostatic acid phosphatase, 259
Steroids, acetylenic and allenic, effects of, on rat prostate, 255
Streptozotocin (NSC-85998)
with bleomycin and CCNU in a phase II study of patients with metastatic breast cancer, 1365
and 5-FU in the treatment of metastatic gastrointestinal neoplasms, 1375
in the treatment of prostatic cancer, 317
Surgery, radical retropubic prostatectomy, bilateral orchiectomy, estrogen therapy, and chemotherapy (5-FU and cyclophosphamide) for advanced prostatic cancer, 313

T

Tamoxifen (NSC-180973), antiestrogen, in the treatment of advanced breast cancer, 899
TEAM (6-thioguanine, cyclophosphamide, cytosine arabinoside, and methyl-CCNU), used in the treatment of refractory acute leukemia, 1397
Testicular cancer *see* Cancer, testicular
Testis, rats, as an immunologically privileged site, 217
Tetrahydrofolate coenzymes, regulatory control of, in folate auxotrophs, 533
Tetrahydrouridine (NSC-112907)
and cytosine arabinoside in mouse tumors, 1355
effect of, on distribution of cytosine arabinoside and its products in mice, dogs, and monkeys, 395
physiologic disposition and effect upon deamination of cytosine arabinoside in man, 1347
***meso*-Tetra(*p*-sulfophenyl)porphine (NSC-177391)**, localization of, in murine sarcoma virus-induced tumor-bearing mice, 1297
6-Thioguanine (NSC-752)
combined with cyclophosphamide, cytosine arabinoside, and methyl-CCNU (TEAM) in the treatment of refractory acute leukemia, 1397
microbiologic assay for, 597
ThioTEPA (NSC-6396)
intrathecal, treatment of malignant meningeal disease: phase II study, 885
in the treatment of renal cell carcinoma, 1585
Thoracic cancer *see* Cancer, thoracic
Thyroid cancer *see* Cancer, thyroid
Thyroxine, 5-FU-induced increase of, in serum of patients with advanced breast cancer, 1291
Tomography, whole-body computed, in the diagnosis of abdominal and thoracic malignancy: review of 600 cases, 1537
Triazinate (NSC-139105), effect of, versus enzymatic folate depletion on folate and thymidine enzymes in cultured mammalian cells, 539
Triiodothyronine, 5-FU-induced increase of, in serum of patients with advanced breast cancer, 1291
Trophoblastic cancer *see* Cancer, trophoblastic
Tumor size, as a factor in sensitivity to therapy, 1307
Tumor systems in animals
Adenocarcinoma E0771, combination of cytosine arabinoside and tetrahydrouridine in, 1355
chemotherapy of human lung, ovarian, colonic, and renal carcinomas in T-lymphocyte-deficient mice, 451
Dunn osteosarcoma in mice, effect of sequence of combined radiation and cyclophosphamide regimens on, 1569
Dunning R3327H rat prostatic adenocarcinoma, char-

acterization of, an appropriate animal model for prostatic cancer, 273
Gross leukemia, antitumor activity of 4-demethoxydaunorubicin administered orally, 893
hepatoma cell lines in rats, a new antineoplastic amino acid derivative (A-924) tested in, 1577
HT 67, a new high-glucuronidase transplantable mouse tumor curable by aniline mustard therapy, 909
Lewis lung carcinoma
combination of cytosine arabinoside and tetrahydrouridine in, 1355
differential distribution in metastatic tissue versus primary tumor of antitumor agents in, 1319
pulmonary metastases of—cell kinetics and response to cyclophosphamide at different sizes, 29
L1210 leukemia
advanced, chemotherapy of, with platinum compounds in combination with other antitumor agents, 445
effect of homo-aza-steroidal ester of [*p*-[bis(2-chloroethyl)amino]phenyl]acetic acid, 37
enhancement of antileukemic effect with the combination of OK-432 and 5-FU, 17
preparation and antitumor evaluation in, of water-soluble derivatives of dichloro(1,2-diaminocyclohexane)platinum(II), 1519
Madison 109 lung carcinoma, characterization and responsiveness of, to various antitumor agents, 1459
MA-21224 transplantable mammary carcinoma, selective tumor DNA synthesis inhibition: in vivo prodrug activation by an exogenous enzyme, 1489
murine myeloid leukemia of the RFM mouse, pathophysiology and drug sensitivity, 1259
murine sarcoma virus-induced rhabdomyosarcoma, localization of *meso*-tetra(*p*-sulfophenyl)porphine in, 1297
new animal model of leptomeningeal neoplasms, 733
Novikoff hepatoma cells from rats, effects of adriamycin and actinomycin D on nucleolar morphology: a simple biologic assay, 1253
P388 leukemia
antitumor activity of some amino acid metal systems in, 469
effect of homo-aza-steroidal ester of [*p*-[bis(2-chloroethyl)amino]phenyl]acetic acid, 37
prostate adenocarcinoma in rats, investigations on, 153
Sarcoma 180
antitumor activity of 4-demethoxydaunorubicin administered orally, 893
ascitic, solid, and intracranial, toxicity and responsiveness of, to DDMP [pyrimidine, 2,4-diamino-5-(3,4-dichlorophenyl)-6-methyl-] and DDMP with citrovorum factor, 1325
differential distribution in metastatic tissue versus primary tumor, of antitumor agents in, 1319
Sarcoma 180 Japan, combination of cytosine arabinoside and tetrahydrouridine in, 1355
Sarcoma T241, combination of cytosine arabinoside and tetrahydrouridine in, 1355
transplanted GR mouse mammary tumors, effects of treatment with cyclophosphamide on hormone-dependent and hormone-independent tumor cells in, 861
Walker 256 carcinosarcoma, differential distribution in metastatic tissue versus primary tumor of antitumor agents in, 1319

V

Vinblastine (NSC-49842)
causing pain in tumors, 1735
combined with 5-azacytidine and VP-16-213 in previously treated patients with acute nonlymphocytic leukemia, 1599
combined with bleomycin, Raynaud's phenomenon as a side effect of treatment for testicular carcinoma, 925
in the treatment of renal cell carcinoma, 1585
Vincristine (NSC-67574)
with CCNU, cyclophosphamide, and procarbazine followed by radiation for oat cell carcinoma of the lung, 1
with cyclophosphamide and methotrexate followed by radiation for oat cell carcinoma of the lung, 1
with cyclophosphamide and prednisone in the treatment of non-Hodgkin's lymphoma, 1079
with cyclophosphamide, methotrexate, 5-FU, and prednisone in the treatment of advanced breast cancer, 47
combined with adriamycin and bleomycin in the treatment of men with metastatic germ-cell tumors, 1447
combined with adriamycin and procarbazine in previously treated patients with small cell lung carcinoma, 485
combined with adriamycin, cyclophosphamide, methotrexate, and citrovorum factor rescue in the treatment of metastatic breast cancer, phase II study, 1527
combined with bleomycin, adriamycin, CCNU, and mechlorethamine (BACON) and compared to mechlorethamine, adriamycin, and CCNU (NAC) in the treatment of squamous lung cancer, 1623
combined with cyclophosphamide and prednisone in the treatment of stage IV non-Hodgkin's lymphomas, 1117
combined with cyclophosphamide and prednisone or with cyclophosphamide, prednisone, and BCNU in non-Hodgkin's lymphoma, 1085
combined with cyclophosphamide, methyl-CCNU, and bleomycin in the treatment of lung carcinoma, 59
combined with cyclophosphamide, methotrexate, citrovorum factor rescue, and cytosine arabinoside in the treatment of diffuse histiocytic lymphoma, 1109
combined with DTIC and methyl-CCNU in the treatment of disseminated malignant melanoma, 881
combined with hexamethylmelamine and methotrexate in advanced neoplasms, 919
combined with procarbazine, prednisone, and BCNU in the primary treatment of disseminated Hodgkin's disease, 789
distribution and metabolism of, in mice, rats, dogs, and monkeys, 1269

and procarbazine, cyclophosphamide, and CCNU combined with radiation therapy in the treatment of extensive oat cell lung cancer, 1427
in the treatment of multiple myeloma in remission, 381
used in combination immunochemotherapy of oat cell carcinoma of the lung, 343
Vindesine sulfate (NSC-245467), phase II study of, in the therapy for advanced renal carcinoma, 1727
VM-26 (NSC-122819)
combined with adriamycin in the treatment of metastatic transitional cell carcinoma, 87
combined with CCNU and bleomycin, enhancement of bone marrow toxicity, in patients with malignant brain tumors, 1695
combined with iv methyl-CCNU and cranial irradiation in the therapy for malignant brain tumors, 1715
in the treatment of childhood neuroblastoma, 1243
VP-16-213 (NSC-141540)
combined with vinblastine and 5-azacytidine in previously treated patients with acute nonlymphocytic leukemia, 1599
lack of severe hypotension with, administered directly iv, 1411
phase II clinical trial of weekly administration of, in the treatment of small cell lung carcinoma, 489
phase II study, combined with cyclophosphamide or adriamycin in the treatment of small cell lung cancer, 93

W

Walker 256 carcinosarcoma *see* Tumor systems in animals
WR-2721 *see* *S*-2-(3-Aminopropylamino)ethylphosphorothioate

X

Xenografts, human lung tumor, regression of, induced by water-soluble analogs of hexamethylmelamine, 927

Author Index

A

Abeloff MD, 1685
Adamson RH, 1471
Adler S, 749
Áfra D, 841
Ahluwalia BS, 167
Ahmann DL, 81
Ahn YS, 1379
Aisner J, 499
Alberts DS, 381
Albrecht AM, 533
Alexander M, 1, 1427
Alison R, 1129
Alonso MC, 899
Amare M, 905
Anandaraj S, 1471
Anderson T, 1017, 1057
Appelbaum FR, 1397
Arkun SN, 1675
Armitage JO, 1721
Aroesty J, 1665
Arwidi A, 1527
Arya SK, 113
Aslam J, 371
Atkins LM, 445, 1519
Austin DF, 187
Avery T, 1243

B

Baffi PR, 1738
Bagshaw MA, 297
Baker L, 51, 59, 463, 1565, 1573, 1579, 1595
Balasa RW, 108
Band PR, 1365
Banks SE, 473
Banner RJ, 469
Baracu I, 929
Barlogie B, 425
Bartolucci AA, 1085, 1675
Barzell WE, 97
Bateman JR, 1383
Batzold FH, 255
Bauer H, 181
Bauer M, 325
Bean C, 477
Beex L, 1291
Bekesi JG, 901
Benckhuysen C, 561
Bender RA, 1017, 1057, 1231
Benito E, 899
Benjamin RS, 1485, 1495, 1699
Bennett JM, 1079
Berard CW, 953, 1037, 1057, 1153
Berd D, 1109
Berenzweig MS, 77
Berger JE, 227
Berlinger NT, 613
Bernstein I, 83
Bertino JR, 539, 667, 1109
Bertolli TA, 187
Bhuthimethee V, 419
Billups LH, 1459
Bisel HF, 81
Bjornsson S, 89, 1259
Blackard C, 181
Blasberg RG, 625, 633
Blessing J, 1533
Bleyer WA, 703, 1419
Block JB, 1665
Blom H, 1097
Bloomfield CD, 963
Bodey GP, 437, 905, 1699
Bolton JH, 43
Bonadonna G, 355, 769, 1117
Bondy PK, 1647
Boronow R, 1533
Bosch FX, 899
Boston B, 1607
Bottomley R, 905, 1623
Bowen JM, 119
Brahm M, 47
Brannen GE, 211
Brattain MG, 157
Braylan RC, 953
Brereton HD, 1017, 1153
Broder LE, 349, 485, 489, 1589
Broggini M, 1319
Brouet J-C, 1179
Broughton A, 1509, 1631
Broun GO, 1379
Brown B, 647
Brown RK, 1637
Brown SM, 187
Brownlee RW, 1595
Brunner KW, 1411
Brunning RD, 963
Buchman VM, 895
Budman D, 1733
Buell D, 1001
Bukowski RM, 1375
Bull M, 485
Bunn PA, Jr, 333
Burchenal JH, 657
Burgess MA, 437, 471, 1447

Burke GP, 477
Burleson GR, 153
Burns CP, 1721
Buroker T, 463, 1579
Busch H, 1253
Busch RK, 1253
Bush RS, 1129
Butler JJ, 1137
Byar DP, 223
Byfield JE, 497
Byrne GE, Jr, 935

C

Caceres E, 498
Cadman EC, 667, 1109
Calvert AH, 1647
Canellos GP, 993, 1153, 1365
Cangir A, 69
Cantor ML, 603
Capizzi RL, 1607
Carbone PP, 325, 1079, 1249
Carlevarini LA, 723
Carmody J, 1389
Carolla R, 1731
Carr DT, 93, 1339
Carrano CJ, 1297
Carter SM, 451
Carter WA, 113
Carter WH, Jr, 849
Casazza AM, 893
Cashmore AR, 667
Cassady JR, 675, 1001
Cassileth PA, 1441
Castellino R, 981
Catane R, 307, 1738
Catsoulacos P, 37
Cavalli F, 1411
Cavallito JC, 559
Chabner BA, 108, 495, 651, 709, 993, 1017, 1057, 1153
Chaffey JT, 1149
Chan H, 797
Chang CF, 153
Chang P, 1719
Charlson AJ, 469
Chary KK, 367
Chase EM, 1617
Chassagne D, 329
Chello PL, 539
Chen FP, 805, 1269
Chernik NL, 733
Choe BK, 201
Choffel C, 343
Chou TC, 617
Chu TM, 161, 193, 317
Ciesielka W, 751
Citrin DL, 1249
Clark TD, 815
Clarke SA, 451, 927
Clarkson BD, 7
Coffey DS, 211, 273
Cohen MH, 333, 349, 485, 489, 1385, 1589
Coleman M, 1731
Coles DT, 93, 1339
Collins RD, 971
Colombo T, 1319
Colsky J, 325
Coltman CA, Jr, 1067, 1485
Comis RL, 1631
Connors TA, 451, 927
Cooney DA, 1471
Cooper MR, 1591
Cooper RA, 325
Corle DK, 223
Correa J, 463
Costanzi J, 51, 889, 1623
Court B, 329
Covey DF, 255
Cowie CH, 815
Cowles AL, 519
Creagan ET, 107, 491
Creaven PJ, 349
Creech R, 325
Crews SL, 849
Crooke ST, 1509, 1631
Cseténvi J, 841
Cullinan SA, 1725
Cumber AJ, 927
Cunningham T, 919
Currie VE, 1727, 1733
Cvitkovic E, 359

D

da Costa M, 575
Dalton RJ, 481
Daniels JR, 1, 1427
Daskal Y, 1253
Davis HL, Jr, 759, 1191
De Lena M, 355, 769
De Palo GM, 355
Debusscher L, 1433
Decker DG, 913
Dedrick RL, 513, 703
Denine EP, 409
Depierre A, 343
DeAngelis LM, 539
DeVita VT, 993, 1017, 1057, 1153, 1219, 1223
DeWys WD, 325
Di Marco A, 893
Didolkar MS, 1738
Diggs CH, 1581
DiSaia PJ, 1403, 1533
Djerassi I, 691, 749, 751
Dmochowski L, 119
Donaldson SS, 1199
Donavan M, 919
Donelli MG, 1319
Donsbach RC, 565
Doppman JL, 1537

Dorfman RF, 945, 981, 1085
Dorick DM, 565, 1325
Double JA, 909
Dowling MD, 7
Drewinko B, 425, 1513
Duncan G, 1637
Dunnick NR, 981, 1537
Durant JR, 1085
Durie BGM, 381, 1617

E

Eagan RT, 93, 311, 481, 1339, 1731
East JL, 119
Eckhardt S, 841
Edelstein R, 343
Edmonson JH, 81, 913
Einhorn LH, 881, 1447, 1631
Eisenberger MA, 1589
Ekert H, 1736
El Dareer SM, 395, 805, 1269, 1279
El-Mahdi AM, 1569
Ernster VL, 187
Ettinger DS, 1685
Evans AE, 83
Evans WE, 797
Eyre HJ, 51
Ezdinli E, 1079

F

Faguet GB, 1379
Falletta J, 69
Farber L, 1109
Fenstermacher JD, 519
Filler RM, 675
Finklestein J, 83
Fischer JJ, 825
Fisher JM, 1407
Fisher RI, 999, 1057
Flaherty M, 1097
Fletcher WS, 55
Foley JF, 101
Forcier RJ, 477
Fossieck BE, Jr, 333, 349, 485, 489
Fraile RJ, 59
Frank MM, 953
Freeman AI, 727, 835
Frei E III, 675, 695, 1125, 1209
Freiha FS, 297
Friedman AE, 259
Frytak S, 81, 93, 491, 1339, 1725
Fujita H, 1577
Fuller LM, 1137
Furnas B, 881
Furner RL, 1637

G

Gaeta JF, 227, 317
Gailani S, 161
Gajl-Peczalska KJ, 963
Gale GR, 445, 1519
Gale RP, 469
Gamarra MC, 227
Gamble JF, 1137
Gams RA, 1085
Gangji D, 1695
Garattini S, 1319
Garrett TJ, 7
Gaston MR, 103
Gaumont Y, 647
Geder L, 139
Gee TS, 7
Gehan EA, 1137
Geran RI, 1459
Gerold FP, 359
Ghavimi F, 681
Gibbons RP, 317
Gisolfi AL, 779
Gittes RF, 217
Gizoni C, 643
Glatstein EJ, 1, 981, 1199, 1427
Glidewell O, 1097
Goffinet DR, 981
Goldberg NH, 1393
Goldin A, 103
Goldman ID, 549
Goodwin JW, 1413
Gorbunova VA, 1705
Gordon C, 643, 1347
Gordon DS, 1
Gospodarowicz M, 1129
Gottlieb JA, 51, 437, 1447
Grabin ME, 375
Grabstald H, 97
Grace WR, 477
Graffi A, 1489
Graw RG, Jr, 1397
Grayhack JT, 205
Green A, 1243
Green C, 1513
Greenberg BR, 1383
Greenstreet RL, 1375
Groppe CW, Jr, 1375
Gutin PH, 885, 1715
Gutterman JU, 471

H

Haas CD, 1413
Haggard ME, 69
Haghbin M, 661
Hahn DM, 1585
Hahn RG, 81, 491, 1725
Hall SW, 1495

Hammond GD, 83
Hande KR, 999, 1393
Hanka LJ, 591
Hansen HH, 1603
Harada M, 223, 1603
Harrap KR, 1647
Harrison DT, 789
Harrison SD, Jr, 409
Harvey HA, 925
Hasegawa Y, 73
Haut A, 905, 1617
Hayes A, 1243
Hayes D, 1097
Head GL, 1537
Heilbrun L, 1623
Hellman S, 1149, 1175
Helman LJ, 745, 759
Henderson ES, 89, 367, 869
Herman TS, 875, 1009
Hersh EM, 471
Herson J, 167, 855
Herz ML, 419
Herzig GP, 1397
Heshmat MY, 167
Hession C, 1355
Heston WDW, 273
Heusinkveld RS, 875
Hewlett JS, 905, 1375, 1595
Higby DJ, 367, 835, 869
Hildebrand J, 1695
Hill DL, 395, 805, 1269, 1279
Hill RP, 29
Ho DHW, 717
Holland JF, 389, 901, 1097
Holoye PY, 87
Holyoke ED, 1738
Hoogstraten B, 1413, 1623
Horoszewicz JS, 113
Horváth IP, 841
Horwitz S, 1561
Houchens DP, 103
Houghton AL, 923
Howell SB, 1389
Howells R, 849
Hreshchyshyn M, 1533
Hsieh S, 749
Huang AT, 1735
Hubbard SP, 993, 1017
Humphrey GB, 69
Hurley TH, 43
Hutchison DJ, 505, 597, 603, 613, 1657

I

Ichimura H, 1577
Ihde DC, 333, 485, 489, 1385
Ingle JN, 1339
Institóris L, 841
Iqbal MP, 575
Isacoff WH, 1665
Israël L, 343, 1365
Israel M, 1209
Izbicki RM, 59, 1573

J

Jackson AG, 167
Jackson MA, 167
Jacobs SA, 651
Jaffe ES, 953
Jaffe N, 675, 1001
Jayaram HN, 1471
Job L, 113
Johns DG, 651
Johnson DE, 87, 119, 317
Johnson GJ, 1079
Johnson RE, 993, 1153
Johnson RK, 103
Johnson SK, 993
Johnston AV, 349
Jones GW, 167
Jones SE, 875, 1009, 1067, 1595, 1617
Jorgensen EO, 913
Juhn SK, 613

K

Kadohama N, 289
Kaighn ME, 147
Kalman MA, 1537
Kamalakar P, 835
Kane RC, 1385
Kaplan BH, 77
Kaplan HS, 981, 1199
Kapoor SK, 167
Kardinal CG, 1383, 1691
Karp DD, 477
Karr JP, 289
Katz ME, 1441
Kaufman J, 1738
Keanan JP, 55
Kelley JM, 1471
Kempson RL, 297
Kennedy BJ, 1731
Kennedy J, 167
Kerpel-Fronius S, 841
Kersey JH, 963
Kerzner L, 1607
Kessinger A, 101
Kiely JM, 65
Kim JS, 691, 749, 751
Kind P, 129
King TJ, 111
Kirdani RY, 289
Kisliuk RL, 647
Klastersky J, 1433
Klemperer M, 83
Kloppenborg P, 1291

Knesek JE, 119
Knospe WH, 1379
Komp DM, 69, 855, 1373
Koshimura S, 17
Kovi J, 167
Krakoff IH, 723, 1347
Kramer BS, 1397
Kreis W, 643, 723, 1347, 1355
Kreisberg JI, 157
Kuciel R, 193
Kvols LK, 311, 1339
Kwasniewski B, 161

L

Lagasse LD, 1403
Lair SV, 1679
Lane M, 889
Layard M, 1411
Lee BJ, 7
Lee C, 205
Lee RE, 93
Legha SS, 1699
Lehane DE, 889, 1623
Leikin S, 83
Leite CJ, 1413
Lemon HM, 101
Lenhard RE, Jr, 1079
Leone L, 1731
Levi JA, 885, 1301
Levine AS, 1397
LeRoy AF, 375
Li LH, 815
Li RW, 1499
Lichinitser MR, 1705
Lichtenfeld KM, 1599
Lincoln TL, 1665
Lindholm C–E, 1527
Lipton A, 925
Livingston RB, 1623
Lloyd RE, 875
Lo PS, 825
Loew J, 1561
Longacre D, 919
Loo TL, 1513
Lozzio BB, 1679
Lozzio CB, 1679
Lucas AO, 167
Lucas VS, 1735
Luce JK, 1067, 1691
Lukes RJ, 971
Lumb G, 901

M

Machado EA, 1679
Machin D, 1695
Madison RM, 1459
Maldonado N, 1379
Malkasian GD, Jr, 913
Mandel J, 181
Mandel SA, 187
Mangan CF, 1403
Manthei RW, 55
Mäntylä M, 1709
Marks TA, 103, 1459
Martin RG, 1137
Maruyama K, 119
Masaoka T, 73
Matthews MJ, 333
Matthews RN, 1738
Mattsson W, 1527
Maurer LH, 477
Mavligit GM, 471
Maxwell I, 371
McArdle NT, 469
McCombs RM, 131
McConnell S, 1297
McDonald B, 1573
McDonald I, 201
McHugh R, 181
McIntire KR, 1385
McIntyre OR, 477, 1097
McKelvey EM, 1067, 1185
McKenzie M, 1579
McLaughlin WL, 419
McLimans WF, 161
McLoughlin MG, 265
McMahon LJ, 875
McPherson TA, 105
McQueen CA, 539
Mehta BM, 505, 597, 603, 613, 681, 779, 1657
Meischen SJ, 445, 1519
Mellett LB, 395, 527, 805, 1269, 1279
Menon M, 265
Merker PC, 603
Merrin C, 313
Merski J, 1253
Metter GE, 55
Meyers MB, 723
Miale T, 855
Mickey DD, 133
Middleman MP, 7
Miller A, 1579
Miller RC, 875
Milleron B, 343
Mills RC, 477
Minna JD, 333, 349, 485, 489, 1385
Minow RA, 437
Mitchley BCV, 451, 927
Mittelman A, 307
Moccio DM, 565, 1325
Moertel CG, 107, 491, 1725
Moloney WC, 1149
Monfardini S, 1117
Moon TE, 905, 1067, 1185
Moran ME, 498
Morgan LR, 1453
Morgan S, 1373
Mori M, 1259

Morris D, 499
Morrison FS, 51, 905
Morrison PF, 1665
Morrow CP, 1369, 1403
Mosende C, 681, 779
Moss SE, 55
Mostofi FK, 223
Moulder JE, 825
Mouridsen HT, 47, 1603
Mugera GM, 1333
Muggia FM, 77, 759, 1191, 1411, 1561
Mulligan LT, Jr, 395
Müntzing J, 289
Murphy GP, 111, 193, 289, 307, 317
Murphy SB, 1161
Muss HB, 1591
Myers RP, 311

N

Nakamura H, 73
Nanba K, 953
Nayak N, 749
Nealon TF, 55
Neidle S, 928
Neiman PE, 789
Nelsen TS, 981
Nelson RS, 1699
Neville AM, 451
Nichol CA, 559
Niculescu-Duvăz I, 929
Nirenberg A, 681, 779
Nissen NI, 1097
Nkposong EO, 167
Nordman EM, 1709
Norton L, 1057, 1307
Nouwynck C, 1695
Novikova LA, 895

O

O'Bryan RM, 51, 1485
O'Connell MJ 65, 81, 491, 1725
O'Fallon JR, 1339
Ohanissian H, 749
Ohnuma T, 389
Ohtsuki Y, 119
Olisa E, 167
Oliver L, 205
Omura GA, 915, 1379, 1533
Osterlind K, 1603

P

Padilla F, 889
Pajak TF, 1097, 1383
Paladine W, 919
Palmer RL, 1623, 1711
Palshof T, 47, 1603
Park R, 1533
Pasmantier MW, 1731
Pastore EJ, 647
Pásztor E, 841
Paterson AHG, 105
Patlak CS, 633
Paul BD, 259
Paulson DF, 133
Pavlotsky AI, 895
Peckham JC, 409
Penta JS, 745, 759
Perevodchikova NI, 1705
Philips FS, 617
Pinedo HM, 709
Pistenma DA, 297
Pitman SW, 695
Pocock SJ, 1079, 1365
Pollard M, 153
Pontes EJ, 201
Portlock CS, 1049
Posey LE, 1453
Posner JB, 733
Pratesi G, 893
Pratt CB, 797, 1243
Preisler HD, 89, 1259
Prestayko AW, 1631
Pretlow TG II, 157
Preud'homme J-L, 1179
Prevost JM, 1433
Prout GR, 317

Q

Quagliana JM, 51
Quinnan GV, Jr, 1607

R

Rabinovitz M, 1407
Radzikhovskaya RM, 895
Ragab AH, 69
Rahbek I, 47
Ramirez G, 55
Rapp F, 139
Raso V, 585
Ravry MJR, 106
Ray GR, 297
Reif AE, 1499
Reimer RR, 999
Reitemeier RJ, 491, 1725
Richards F II, 1591
Richman SP, 471
Rinehart KL, Jr, 815
Rivera G, 1243
Robinson CH, 255
Robinson CM, 1499

Robinson FO, 161
Robinson MRG, 923
Rodriguez LH, 87
Rohner TJ, 139
Rohwedder JJ, 1399
Romolo JL, 1393
Rose NR, 201
Rosen G, 681, 779
Rosen M, 1607
Rosenberg SA, 981, 1023, 1029, 1049, 1199, 1393
Rosenoff SH, 1017
Rosenthal DS, 1149
Rosenthal S, 108
Ross A, 1291
Ross WCJ, 927
Ross WE, 495
Rothenberg SP, 575
Rotkin ID, 173
Rozencweig M, 759, 1191, 1411
Rubin J, 93, 491, 1339, 1725
Ruckdeschel JC, 1585
Ryoyama K, 17
Ryssel HJ, 1411

S

Sacks ST, 187
Sagastume E, 1399
Saiki JH, 905, 1595
Saiontz HI, 481
Sakurai T, 1577
Salmon SE, 381, 875
Samal BA, 1711
Samson MK, 59, 1573, 1579
Samuels ML, 87
Sandberg AA, 289
Sanford EJ, 139
Sarlos IJ, 259
Saroff J, 317
Sato H, 1577
Sawicki WL, 667
Scarlett J, 181
Schaner EG, 1537
Schiffman FJ, 1407
Schimpff SC, 1301, 1585
Schlossman S, 1209
Schmid FA, 473
Schmidt JD, 317
Schuman LM, 181
Schutt AJ, 491, 1725
Schwabe K, 1489
Schwartz LA, 463
Schwartz P, 1519
Scott WW, 273, 317
Scully K, 1355
Sears M, 1365
Selawry OS, 349
Seligman AM, 259
Seligman M, 1375
Seligmann M, 1179
Selvin S, 187
Seman G, 119
Senda N, 73
Serrano JA, 259
Sexauer CL, 855, 1373
Shaeffer J, 1569
Shah J, 359
Shah P, 1565
Shapiro WR, 505, 633, 733, 753
Shetty MR, 501
Shibata H, 73
Shullenberger CC, 1137
Shulman K, 691
Sigel CW, 559
Silberman H, 785
Silva-Sosa M, 855
Silver RT, 1731
Silverstein MN, 65
Simon R, 1307, 1589
Sinkovics JG, 1137
Sinks LF, 727, 835
Sirotnak FM, 565, 1325
Skeel RT, 667
Slavik M, 745
Slawson RG, 1301
Sluyser M, 861
Smalley RV, 1379
Smals A, 1291
Smetana K, 1253
Smith AB, 445, 1519
Smith PH, 923
Smith PJ, 1736
Smith RC, 477
Smolev JK, 273
Smyth AC, 1581
Solomon A, 785
Sonntag RW, 1411
Soper WT, 759
Soricelli A, 1355
Sponzo R, 919
Spurr CL, 1591
Stanley JA, 29
Stephens RL, 1413, 1595
Sternberger NJ, 259
Stock CC, 473, 509
Stoller RG, 651
Stone KR, 133
Stone MP, 133
Strong EW, 359
Strong JE, 1509, 1631
Struck RF, 1279
Stuckey WJ, 1623
Sturgeon J, 1129
Sufrin G, 161, 289
Sullivan JR, 43
Sussman H, 1607
Svet-Moldavsky GJ, 895
Swaiminathan A, 55
Swinerton KD, 367
Sydow G, 1489
Számel I, 841
Szlovik F, 841

T

Takubo T, 73
Tananis CE, 265
Tattersall MHN, 647
Tejada F, 1589
Teutsch C, 925
Thigpen JT, 1485
Thomas ED, 1713
Thomas HE, Jr, 1607
Tillery K, 395, 805
Toloknov BO, 895
Tormey DC, 1249
Tornyos K, 785
Toyoshima S, 1577
Traggis D, 675, 1001
Trainor KE, 469
Tranum BL, 889, 1617, 1711
Trump BF, 223
Tschiersch B, 1489
Tsutsui M, 1297
Tucker WG, 51, 1617
Twiggs LB, 1369
Tyce GM, 107

U

Ueda T, 73
Ushio Y, 733

V

Vaitkevicius VK, 59, 463, 1565, 1573, 1579, 1595
Valagussa P, 769
Valdivieso M, 1495, 1699
Valenzuela L, 193
Van Echo DA, 1599
van Eys J, 1373
Van Scoy-Mosher MB, 104
Vaughn CB, 1617, 1711
Vélez-García E, 1675
Vidal P, 617
Viladiu P, 899
Villa E, 1117
Vogl SE, 901
Vogler WR, 1379, 1675
von Eyben F, 1527
Von Hoff DD, 745, 759, 1411

W

Walker EM, Jr, 445, 1519
Walker MD, 885, 1715
Wallace HJ, Jr, 835, 869
Wallace S, 1137
Walsh PC, 265
Wampler GL, 37, 849
Wang JJ, 727
Wang MC, 193
Ward JM, 375, 1333
Warnke R, 981
Warren RD, 1231
Wasserkrug HL, 259
Waters KD, 1736
Watson RC, 97
Watton EC, 469
Watts H, 675
Weerts-Ruhl D, 1433
Weick JK, 1375
Weiden PL, 1713
Weiner JM, 83
Weinstein H, 1001
Weiss AJ, 55
Weiss GB, 1713
Weiss R, 869, 1731
Wendel EF, 205
White DR, 1591
White VM, 395, 805, 1269, 1279
White WL, 65
Whitmore WF, 97, 217
Wiernik PH, 499, 885, 1301, 1581, 1585, 1599, 1719
Wilbur D, 869
Williams AO, 167
Williams C, 1427
Williams CL, 349
Willis KL, 1665
Wilson HE, 905
Winkelstein W, Jr, 187
Wittes RE, 359, 1733
Wong PP, 1727
Woodcock TM, 643, 723, 1347
Woodman RJ, 1459
Woolley JL, 559
Workman P, 909

Y

Yagoda A, 97, 1727
Yoshida H, 119
Yoshitake J, 73
Young CW, 7, 1727
Young DF, 733
Young DM, 375
Young RC, 993, 1017, 1057, 1153

Z

Zaharko DS, 513
Zeigel RF, 113
Zucali R, 769
Zweig JI, 419

Reviewers

We wish to thank the following Reviewers who participated in evaluating the manuscripts submitted to *Cancer Treatment Reports* during the past year:

Betty J. Abbott
Martin D. Abeloff
David Abraham
Richard H. Adamson
David L. Ahmann
Joseph Aisner
David S. Alberts
Philip O. Alderson
Tom Anderson
Fred J. Ansfield
Bach Ardalan
Donald Armstrong
E. Ronald Atkinson
Nicholas R. Bachur
Malcolm A. Bagshaw
Richard F. Bakemeier
Laurence H. Baker
James E. Balow
M. Barclay
Joseph J. Barlow
Fred Baskin
Joseph R. Bateman
Steve Baylin
John L. Bear
John A. Beisler
Robert E. Bellet
Richard A. Bender
Robert S. Benjamin
John E. Bennett
Joseph W. Bennett
John A. Benvenuto
Daniel E. Bergsagel
Jacob D. Bitran
R. Michael Blaese
W. Archie Bleyer
Johannes Blom
Clara Derber Bloomfield
Ronald H. Blum
George Blumenshein
Avrum Bluming
Gerald P. Bodey, Jr.
Arthur E. Bogden
Dane R. Boggs
Gianni Bonadonna
Michael R. Boyd
Matthews O. Bradley
George Brecher
Wayne Brenckman
Murray Brennan
Robert Brennan
Harmar D. Brereton
Lawrence E. Broder
Samuel Broder
Samuel C. Brooks
J. Martin Brown
Howard W. Bruckner
C. Dean Buckner
Joan M. Bull
Philip J. Burke
Thomas Buroker
Harris Busch
George F. Cahill, Jr.
Glyn G. Caldwell
George P. Canellos
Robert Capizzi
Paul P. Carbone
Stephen K. Carter
Marjory Chadwick
Kenneth K. Chan
Paul Chang
C. C. Cheng
Colin F. Chignell
Michael A. Chirigos
Delia Chiuten
Bayard Clarkson
William R. Cobb
Carmel J. Cohen
Jordan L. Cohen
Martin H. Cohen
Philip Cohen
Seymour S. Cohen
Jerry M. Collins
Charles A. Coltman, Jr.
Robert L. Comis
T. A. Connors
James F. Conroy
T. H. Corbett
James C. Cradock
William A. Creasey
Patrick J. Creaven
Frank J. Cummings
Gordon B. Cutler, Jr.
Esteban Cvitkovic
Richard L. Cysyk
Jack D. Davidson
Thomas E. Davis
Robert L. Dedrick
Ralph A. DeFronzo
E. Paul Denine
Myles R. Desner
Charles H. Diggs
James V. Dingell
Robert L. Dixon
Raphael Dolin
James H. Doroshow
Thomas J. Dougherty
Benjamin Drewinko
Robert T. Eagan
Sandor Eckhardt
Richard L. Edelson
John H. Edmonson
Clarence E. Ehrlich
Frederick R. Eilber
Lawrence H. Einhorn
Elias G. Elias
Mortimer M. Elkind
Robert R. Engel
W. King Engel
William Ensminger
George C. Escher
Robert J. Esterhay, Jr.
David S. Ettinger
Audrey E. Evans
Geoffrey Falkson
Philip Felig
Joseph D. Fenstermacher
Victor J. Ferrans
Jerry Z. Finklestein
James J. Fisher
Richard I. Fisher
L. Flóhe
Roger M. Folk
Emil Frei III
Emil J Freireich
Michael A. Friedman
Orrie M. Friedman
George F. Fritch
Ruth A. Fugmann
Glen R. Gale
Robert P. Gale
Joseph E. Gallelli
Robert C. Gallo
Silvio Garattini
Harold Gaya
Ruth I. Geran
John E. Gerich
Sandra J. Ginsberg
Beppino C. Giovanella
Tullio Giraldi
Eli Glatstein
Daniel L. Glaubiger
Anthony J. Glazko
Robert B. Golbey
Joseph Gold
Ira S. Goldenberg
J. Goldie
Robert Goodman
Edward J. Gralla
Theodore E. Gram
Gerald B. Grindey
Daniel P. Griswold, Jr.
Joseph F. Gross
Saul B. Gusberg
Jordan U. Gutterman
Davis M. Hahn
Thomas C. Hall
Daniel Haller
Kenneth R. Hande
Heine H. Hansen
Charles M. Haskell
Charles Heidelberger
Samuel Hellman
Lee Helman
Edward S. Henderson

J. Frank Henderson
David W. Henry
Donald J. Higby
George A. Higgins
Donald L. Hill
John Hilton
Dah Hsi Wang Ho
Paul B. Hoffer
John Holcenberg
James F. Holland
Paul Y. Holoye
Barth Hoogstraten
John Horton
Daniel Hoth
David P. Houchens
William J. Hrushesky
David H. Huffman
Robert B. Hurlbert
Dorris J. Hutchison
Daniel C. Ihde
James N. Ingle
William H. Isacoff
Mervyn Israel
David Jackson
Edwin M. Jacobs
Samuel A. Jacobs
Norman Jaffe
Birger Jansson
David G. Johns
Ralph E. Johnson
Randall K. Johnson
Gerald S. Johnston
Stephen E. Jones
C. Ronald Kahn
Herbert Kaizer
Richard S. Kaplan
Stanley A. Kaplan
Stephen I. Katz
Bernard T. Kaufman
David Kessel
Alfred A. Ketcham
David T. Kiang
Daniel L. Kisner
Michael Klein
Ruth G. Kleinfeld
Ira Kline
Richard A. Knazek
Kurt W. Kohn
Irwin H. Krakoff
Willi Kreis
A. Krishan
Stanford Lamberg
W. R. Laster, Jr.
Paul S. Leitman
Luigi Lenaz
Raymond E. Lenhard, Jr.
Gerald A. LePage
Brigid G. Leventhal
John Levi
Victor A. Levin
Carl C. Levy
Alan A. Lewin
Brian J. Lewis
A. Leyva
Karen Lichtenfeld
Charles L. Litterst
Robert B. Livingston
Harris H. Lloyd
Gershon Y. Locker
Jacob J. Lokich
Pavel L. Lomen
Ti Li Loo
William B. Looney
D. Lynn Loriaux
James K. Luce
David B. Ludlum
Robert J. Lutz
R. R. Macdonald
Richard J. Mangi
Nathan Mantel
Alberto M. Marmont
John C. Marsh
Hubert E. May
Robert J. Mayer
Kenneth B. McCredie
William P. McGuire III
Charles McKhann
J. A. R. Mead
L. B. Mellett
Charles E. Mengel
Claude E. Merrin
Enrico Mihich
Rodney R. Million
Malcolm Mitchell
Arnold Mittelman
Edward J. Modest
Charles G. Moertel
Marie Monaco
John A. Montgomery
Leon A. Moore
Harold P. Morris
Seoras D. Morrison
Franco M. Muggia
Gerald P. Murphy
Sharon Murphy
William K. Murphy
Charles E. Myers
Larry Nathanson
Gary L. Neil
Mark E. Nesbit
Larry Norton
G. David Novelli
Peter C. Nowell
Michael J. O'Connell
Takao Ohnuma
Charles L. M. Olweny
J. C. Oram-Smith
Carole O'Toole
Artemio A. Ovejera
Richard J. Owellen
Robert F. Ozols
Lawrence C. Panasci
Rose J. Papac
Robert E. Parks, Jr.
David F. Paulson
Theodore Phillips
Herbert Pinedo
Jose Pino
Julio C. Pita
Philip A. Pizzo
Jacqueline Plowman
William Plunkett
Carol D. Portlock
Charles B. Pratt
Harvey D. Preisler
Cary A. Presant
David J. Prieur
Michael Przybylski
Reginald P. Pugh
Marco Rabinovitz
Nathan Rakieten
Guillermo Ramirez
Victor Raso
Donald J. Reed
M. Maureen Roberts
Michael W. Rohovsky
Mary A. Root
Gerald Rosen
Saul A. Rosenberg
Steven A. Rosenberg
Stephen H. Rosenoff
Griff T. Ross
W. C. J. Ross
Warren E. Ross
Sheldon P. Rothenberg
Marcel Rozencweig
Felix N. Rutledge
Brenda Ryman
Sydney E. Salmon
Melvin L. Samuels
A. A. Sandberg
George W. Santos
Rein Saral
Gregory Sarna
Alan C. Sartorelli
Frank M. Schabel, Jr.
Philip S. Schein
Charles A. Schiffer
Lowell J. Schnipper
Anthony W. Schrecker
Allan J. Schutt
Allen D. Schwartz
William W. Scott
Mary E. Sears
Albert Segaloff
Oleg S. Selawry
Hansjberg J. Senn
Lyle L. Sensenbrenner
Arthur A. Serpick
Stanley E. Shackney
W. Thomas Shier
Sidney Shifrin
M. Michael Sigel
Branimir I. Sikic
Richard M. Simon
Joseph V. Simone
Linda Simpson-Herren
Roland T. Skeel
Norman E. Sladek
Milan Slavik
Julian P. Smith
A. S. Solidaro
Frank C. Sparks
Alexander S. D. Spiers
Samuel D. Spivack
Robert W. Sponzo
Michael B. Sporn
G. Gordon Steel
Richard C. Stein
Frank E. Stockdale
Ronald G. Stoller
Marc J. Straus
James A. Straw
Robert F. Struck

Herman D. Suit
J. Symoens
Robert W. Talley
Charlotte Tan
D. Jane Taylor
Francisco Tejada
Walley J. Temple
Philip S. Thayer
Robert A. Tobey
Douglass C. Tormey
Donald L. Trump
Hamao Umezawa
V. K. Vaitkevicius
Manuel Valdivieso
Frederick Valeriote
David Van Echo
L. M. van Putten
David T. Vistica
Charles L. Vogel
W. R. Vogler
Daniel D. Von Hoff
T. Phillip Waalkes
Michael D. Walker
H. James Wallace, Jr.
Donald F. H. Wallach
Patrick Walsh
Yeu-Ming Wang
Jerrold Ward
Robert D. Warren
Todd H. Wasserman
Bruce L. Webber
Howard D. Weiss
Richard M. Welch
William West
Glynn P. Wheeler
Florence R. White
J. Courtland White
Peter H. Wiernik
Charles B. Wilson
E. Wiltshaw
Robert E. Wittes
Isidore Wodinsky
Mary K. Wolpert
Paul Woolley
Alan Yagoda
Jerome W. Yates
David W. Yesair
Charles W. Young
David M. Young
Lowell S. Young
Robert C. Young
Daniel S. Zaharko
Berton Zbar
Marvin Zelen